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New Zealand has one of the highest rates of colorectal cancer (CRC) in the world, resulting in 
approximately 1200 deaths per year. Optimising the use of adjuvant chemotherapy is one key area 
to reduce CRC-related mortalities. Stage II colon cancer patients are clinically and biologically 
heterogenous. Despite 60-80% of these patients being cured from surgery alone, a subset of these 
patients have a recurrence risk approximating stage III disease. Current risk stratification for the 
administration of adjuvant chemotherapy fails to accurately detect subgroups with different 
prognostic and treatment sensitivities. The discovery and use of molecular biomarkers could be used 
to improve the power of this risk stratification.   
The aim of this exploratory, pilot study was to characterise the expression of potential prognostic 
biomarkers, CD147, microRNA-29a and microRNA-21, in a small pilot cohort of stage II colon cancer 
patients. These markers are strongly associated with aggressiveness and progression in later-stage 
CRC. However, their prognostic potential in early stage colon cancer has not been well defined. 
Additionally, these markers are expressed on tumour-derived extracellular vesicles (tEVs) which can 
home to nearby lymph nodes and promote the spread of cancer. Considering the lymph nodes are 
the first site for dissemination of tumour cells in CRC, tEVs may be particularly relevant to stage II 
colon cancer patients who undergo recurrence. Therefore, the overexpression of these markers 
could be risk-factors in the tumour and draining lymph nodes of these patients. 
Tumour, normal mucosa, and the draining lymph nodes were collected from 13 stage II colon cancer 
patients at the time of surgical resection. Immunohistochemical and quantitative reverse 
transcription PCR techniques were optimised for the detection of CD147, miR-21 and miR-29a in all 
tissue types. The histological morphology of the lymph nodes was also explored.  
We found CD147 was overexpressed in 60% of tumours while miR-21 was overexpressed in 50% of 
tumours. When combined, CD147 and miR-21 potentially highlight specific subsets of patients. 
Tumour-associated expression of miR-21 was dysregulated in the lymph nodes, while tumour-
2 
 
specific CD147 expression was not detectable due to immunological-associated expression. Instead, 
histomorphological findings suggested a large variation in the number, size and shape of lymph node 
B cell compartments. Specifically, changes in follicle and germinal centre size density and size were 
associated with pathological risk factors such as, the presence of lymphatic invasion and T stage.  
CD147 and miR-21 are considerably dysregulated in stage II colon tumours and combined with our 
knowledge of their functionality in preclinical and clinical studies, they represent potential 
prognostic biomarkers for this population. We have also demonstrated how the heterogenous 
histomorphology of B cell compartments, within the lymph nodes, could be a reflection of the 
observed clinical heterogeneity in these patients. Altogether, these potential biomarkers could be 
used to strengthen the current risk stratification in stage II colon cancer patients. While our 
preliminary data warrants validation in a future, larger cohort, our findings demonstrate the clinical 
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CHAPTER 1: INTRODUCTION 
1.1 COLORECTAL CANCER – PREVALENCE, TREATMENT AND OUTCOMES  
1.1.1 PREVALENCE OF COLORECTAL CANCER 
Colorectal cancer (CRC) is the second most frequently diagnosed malignancy in New Zealand (1). 
Over 3000 people are diagnosed with CRC every year, claiming approximately 1200 lives. More than 
75% of these diagnoses occur in people 60 years and older (1). Therefore, with an ageing population 
these statistics are expected to worsen (1, 2). In addition to this, New Zealand and Australia have the 
highest per capita rate of CRC in the world (1). This highlights the burden of CRC in the clinic and the 
tremendous value improved patient outcomes would have for New Zealanders and our health 
system.  
1.1.2 COLORECTAL CANCER AND PATHOLOGICAL STAGING  
CRC is a malignancy of the colon or the rectum whereby colon cancer represents approximately 74% 
of CRC’s with rectal cancers making up the minority (1). Anatomically, the colon and the rectum 
make up the majority of the large intestine with the colon being proximal to the rectosigmoid 
junction and the rectum being distal (3). More than 90% of colorectal carcinomas are 
adenocarcinomas originating from epithelial cells of the mucosa (4) and are characterised by 
glandular structures with varying abnormalities. Other CRC tumours can arise from neuroendocrine, 
squamous, spindle and other cell types, although they are particularly rare (4).  
The TNM staging system is the single strongest prognostic indicator for CRC which assists in 
treatment decision making (1). Histological examination determines the depth of invasion through 
the bowel wall (T), the number of lymph nodes involved (N) and presence of distant metastasis (M), 
ultimately reflecting the extent of disease (5) (Table 1). For stage I the primary tumour has invaded 
the submucosa or the muscularis propria while for stage II it has invaded into the subserosa or 
visceral peritoneum (Table 1). By stage III the cancer has spread to a number of lymph nodes and by 
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stage IV the cancer has spread to distant organs (Table 1). According to the New Zealand PIPER 
Project Statistics (2018), patients diagnosed with stage I colon cancer have an 80% long-term survival 





































1.1.3 TREATMENT OF NON-METASTATIC COLON CANCER  
Surgical resection of the primary tumour is the mainstay of treatment for CRC cancers. However, 
surgical approaches and targeted secondary treatments for colon and rectal cancers are distinct (7, 
8) suggesting they should be considered separately.   
The type and extent of surgery performed largely depends on the location and stage of the tumour 
and the draining lymph nodes (9). For non-metastatic colon cancers where surgeries are performed 
Table 1: TNM Staging System for Colorectal Cancer (5) 
Primary Tumour (T) 
Tx  Tumour cannot be assessed 
Tis Carcinoma in situ 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades subserosa 
T4a Tumour directly invades visceral 
peritoneum 
T4b Tumour invades or has attached to adjacent 
organs/structures 
Regional Lymph Nodes (N) 
Nx Lymph nodes cannot be assessed 
N0 No lymph node metastases 
N1 Metastases in 1-3 lymph nodes 
N2 Metastases in ≥4 lymph nodes 
Distant Metastasis (M) 
Mx Metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases present  
Stage  
I T1-T2 
IIA T3  
IIB T4a  
IIC T4b 
IIIA T1-T2, N1/N1c or T1, N2a 
IIIB T1-T2, N2b or T2-T3, N2a or T3-T4a, N1 /1c 
IIIC T4b, N1-N2 or T2-T3, N2a or T3-T4a, N1-N2 
IV T1-4, N1-2, M1 
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with curative intent, typically the surgical approach is a right/left hemicolectomy, transverse 
colectomy or subtotal colectomy (10). All remove part or the entirety of the colon and draining 
mesenteric lymph nodes. Alternatively, the surgical approach for rectal cancers involves a total 
mesorectal excision (TME) which removes the entire mesorectum and lymph nodes and the intact 
enveloping fascia (11). Consequently, the rate of complications, including anastomotic leakages, 
blood clots and infections, are higher in rectal cancer patients (7). Despite this, associated mortality 
rates are higher in colon cancer patients due to more severe complications post-surgery in this 
group (7). 
Differences also exist in the use of systemic and targeted secondary treatments that aim to reduce 
the risk of recurrence and death between colon and rectal cancer patients (9). For many non-
metastatic colon cancers, treatment post-surgery is limited to chemotherapy while rectal cancer 
surgery can be preceded by neoadjuvant radiotherapy or chemoradiation and less commonly 
adjuvant chemotherapy (9) (figure 1). This is largely due to the high risk of locoregional recurrence in 
rectal cancers as a result of closely surrounding organs and the difficulty of achieving wide surgical 
margins (9). Additionally, colon and rectal cancers are varied in their response to these treatments 
and their long-term recurrence rates (9). While these two cancers are often referred to in 
combination, this study has focused on colon cancers due to disparities in treatment and thus we 




























Figure 1: Basic flow diagram of treatment in non-metastatic CRC.   
Colon and rectal cancer patients undergo surgical resection of the primary tumour. Rectal cancer 
patients may be preceded by neoadjuvant (chemo)radiation before surgery. TNM stage is then 
confirmed after surgical resection. The choice of whether CRC patients undergo adjuvant 
chemotherapy comes down to an informed patient/clinician discussion. Stage I patients rarely 
undergo adjuvant chemotherapy while most stage III patients undergo chemotherapy. The decision 
to administer chemotherapy to stage II patients is usually less straightforward.  
 
 1.1.4 RISK ASSESSMENT IN STAGE II COLON CANCER PATIENTS  
Recurrence following curative-intent surgery and adjuvant therapy in colon cancer is often the 
ultimate cause of death (12). Complete recovery for stage I patients is largely achieved by surgical 
resection alone with these patients having a 5-year survival rate of approximately 90% (13). stage II 
and III patients experience survival rates of approximately 60-80% and 45-80% respectively (13) 
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Despite this, the decision to use chemotherapy, particularly for stage II patients is complicated and 
variable (figure 1). Stage II patients are clinically heterogenous. While most stage II patients only 
require surgical resection for a cure from the disease, a subset of these patients have a survival rate 
approximating or even beyond stage III disease (13). This suggests the TNM staging system alone is 
limited. Therefore, high-risk clinicopathological features are also considered in stage II patients to 
assess their risk of recurrence and guide the administration of chemotherapy. Although no 
consensus exists on the definition of high-risk stage II colon cancer, international guidelines include 
features such as T4a and T4b stage, poorly differentiated pathology, perforation, bowel obstruction, 
perineural invasion, lymphovascular invasion, less than 10-12 lymph nodes examined and positive 
surgical margins (13). But even with incorporation of high-risk features, inconsistencies exist – we 
know that ‘average risk’ patients can recur whilst some ‘high risk’ patients do not (14). Taken 
together it appears the current risk assessment for stage II patients is limited. This is reflected by 
contradictory evidence from clinical trials and discrepancies between international guidelines over 
treatment decisions. 
1.1.5 GUIDELINES FOR TREATMENT DECISIONS  
In contrast to stage II patients, decision making regarding the use and lack of use of adjuvant 
chemotherapy in stage I and III colon cancer patients is mostly straightforward. Stage I patients 
typically only require surgery for complete recovery. Therefore, New Zealand’s Standards of Service 
Provision for Bowel Cancer Patients do not recommend the administration of adjuvant 
chemotherapy to these patients (Table 1) (15). This is consistent with major international guidelines 
such as The National Comprehensive Cancer Network (NCCN) (13) and The European Society of 
Medical Oncology (ESMO) (12) (Table 1). Similarly, the decision to use adjuvant therapy in stage III is 
also relatively uncomplicated. All guidelines strongly recommend the use of adjuvant therapy in all 
stage III patients (Table 1).  
18 
 
Despite this, discrepancies exist between major guidelines over the use of adjuvant chemotherapy in 
stage II colon cancer patients. The NCCN guidelines recommend observation, a clinical trial or a 
course of adjuvant therapy for all stage II patients regardless of high-risk features (although the 
presence of these features should weight the decision towards pro-adjuvant therapy) (13). 
Fluoropyrimidine-based regimens are recommended with the addition of Oxaliplatin only for high-
risk patients (Table 1). ESMO are more conservative in their recommendations that adjuvant 
chemotherapy should not be administered to stage II patients and only considered for patients with 
high-risk features, however no specific requirements of the chemotherapy regime are given (12). 
Similarly, the New Zealand Bowel Cancer Tumour Standards recommend the use of adjuvant 
chemotherapy only for high-risk stage II patients (15). 
Across all guidelines there is a general agreement that the decision to use adjuvant chemotherapy in 
stage II patients should incorporate informed discussions between the patient and physician. This 
involves consideration of prognostic aspects of the disease itself as well as non-disease related 
characteristics such as comorbidities, fitness and age (12). It cannot be absolutely recommended one 










Table 2: International and New Zealand Guidelines for treatment of stage I-III colon cancer 
patients. 
Guidelines  Stage I Stage II Stage II high-risk Stage III 
NCCN 2018 (13) No adj chemo No adj chemo or 
















ESMO 2013 (12) No adj chemo No adj chemo Adj chemo (type 
not specified) for 










NZ Standards of 
Service Provision 
for Bowel Cancer 
Patients 2013 
(15) 
No adj chemo No adj chemo Offered same adj 
chemo regimen 
as stage III 
patients 
Oxaliplatin-based 
a5-FU; fluorouracil and leucovorin calcium combined 
bCapecitabine; 5-FU prodrug 
cFOLFOX, FOLFOX-4, CapeOX, FLOX; Oxaliplatin-based therapies 
1.1.6 EVIDENCE FOR THE USE OF ADJUVANT CHEMOTHERAPY IN STAGE II COLON 
CANCER  
Contradictory evidence from clinical trials has led to discrepancies in guidelines for the use of 
chemotherapy in stage II colon cancer patients. Prior to 2007, there was no compelling evidence for 
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the use of adjuvant chemotherapy in these patients. Some landmark trials (including IMPACT B2, 
Ontario, MOSIAC and NSABP C 07), failed to find any statistically significant benefit for overall 
survival (OS) in stage II patients (16, 17, 18, 19). Trials comparing Fluorouracil (5-FU) with no 
chemotherapy found no benefit in OS however, a trend towards benefit was noticed (16,17, 19). In 
contrast to this, the QUASAR trial, which randomly assigned patients to 5-FU and no chemotherapy, 
found a small but significant 2.9% increase in OS in the treated group (20). Furthermore, the results 
of a 2016 analysis of over 150,000 stage II colon cancer patients, supported the QUASAR trial and 
found treatment was statistically associated with improved survival (HR, 0.76; P<0.001) (21). These 
conflicting results make it difficult to derive the true benefit chemotherapy has for stage II colon 
cancer patients. 
For high-risk stage II colon cancer patients, the role of chemotherapy is still debated. Clinical and 
pathological data required to subgroup patients in large clinical trials are not complete or precise 
enough to evaluate treatment in small patient subsets (20, 22). Therefore, the idea that 
chemotherapy should be administered to high-risk patients is based off high-risk features that are 
only moderately prognostic of outcome in stage II colon cancer. The rationale for providing 
chemotherapy to high risk stage II is the clear benefit seen in stage III colon cancer. A recent meta-
analysis found the 5-year disease-free survival (DFS) in stage III colon cancer patient was 49% for 
those not treated with chemotherapy and 63.6% for those who were (19). Because high-risk stage II 
patients have a 5-year OS closer to stage III disease (13), it may be worth exposing only these 
patients to chemotherapy as opposed to all stage II patients. This is the perspectives of the ESMO 
and NZ guidelines (12, 15): if there is a benefit from treatment in stage II patients it is likely to be 
small and only applicable a subgroup. 
Interestingly, the NCCN suggests chemotherapy be an option for all stage II patients, regardless of 
risk status, because the evidence base for the benefit of fluorouracil (FU)-based therapy in stage III 
patients is clear (13). However, inconsistencies exist within these guidelines. The addition of 
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Oxaliplatin to fluoropyrimidine therapies has a clear benefit in the OS of stage III patients. While 
there is no such evidence in stage II patients the NCCN recommend the addition of Oxaliplatin to 
fluoropyrimidine therapies only to high-risk stage II patients as opposed to all stage II patients (13).  
1.1.7 LIMITATIONS OF THE CURRENT RISK-ASSESSMENT FOR STAGE II PATIENTS  
The ultimate decision of whether to administer adjuvant therapy to stage II patients appears to 
come down to an imperfect risk assessment and non-disease related characteristics. As suggested, 
stage II colon cancer patients represent a clinically heterogeneous group. No large-scale study has 
thoroughly assessed the prognostic and predictive impact of all risk features together. However, 
clinical observations suggest these risk features are only moderately prognostic and lack the ability 
to predict responders from non-responders to chemotherapy in stage II colon cancer patients. This 
suggests the current definition of high-risk patients requires refinement or revaluation. In an ideal 
situation, prognostic indicators would more accurately stratify stage II patients to prevent the over 
or under use of chemotherapy.  
1.2 PROGNOSTIC AND PREDICTIVE MOLECULAR BIOMARKERS IN COLON CANCER  
The search for molecular biomarkers for the management of patients with stage II colon cancer has 
been the focus of a significant amount of intensive research (20, 23, 24). This is largely based on the 
poor predictive power of current pathological and clinical factors, as previously discussed. The 
heterogeneous response to adjuvant chemotherapy seen in this population is likely a reflection of 
heterogeneity at the biological level. Exploring the underlying biology may allow us to detect more 
powerful prognostic and predictive factors (25). For this reason, molecular biomarkers are a 
particularly promising development. Molecular biomarkers could also be additive to 




Indeed, molecular markers already routinely used in the clinic for CRC, such as Carcinoembryonic 
antigen (CEA), KRAS and microsatellite instability status (MSI), have been evaluated for their 
prognostic significance in the context of stage II colon cancer patients. However, only MSI status 
appears to have any clinical relevance to this patient group and is now thus routinely used in the 
clinic for this population. Conflicting evidence exists as to the effectiveness of CEA and KRAS and 
their associations with recurrence are likely weak (23, 24, 26). Importantly, they have not been 
shown to add any more prognostic/predictive information to current clinicopathological risk features 
(23, 24), this is reflected in their infrequent use specifically for stage II colon cancer patients (12, 13). 
Candidate biomarkers such as gene-expression profiling have also emerged in the literature. 
However, these markers seem to also be limited by their weak associations (27) and our poor 
understanding of how their underlying biology is relevant to stage II colon cancer patients. 
1.2.1 MSI – A VALIDATED PRO-NO ADJUVANT PROGNOSTIC BIOMARKER 
MSI is an example of a successful functional biomarker (currently implemented in the clinic) that has 
significant prognostic ability in stage II colon cancer patients. MSI status is a molecular signature of 
deficiency in the mismatch repair (dMMR) proteins and as such, MMR proteins are routinely 
measured by immunohistochemistry (IHC) in the clinic as a surrogate for MSI (28). MSI status has 
mostly been used for the detection of Lynch syndrome, an inherited form of a dMMR system (13). 
The identification of this is particularly important to manage the risk of other cancers for the patient 
and their family members (13). Additionally, this status has been found to hold valuable prognostic 
and predictive information in sporadic cancers which constitutes more than 75% of all MSI tumours 
(29). 
Studies have consistently shown patients with MSI tumours in colon cancer have a better prognosis 
compared to stable tumours (MSS) (30, 31, 32). MSI status is a more relevant prognostic factor in 
stage II patients, as MSI tumours are more common in stage II affecting approximately 22% of stage 
II patients and only 12% of stage III patients (21).  Additionally, using data from the PETACC-3 trial, 
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MSI was potentially more powerful in terms of OS and DFS for stage II patients compared to stage III 
patients treated with adjuvant chemotherapy (33). Stage II had a hazard ratio (HR) for OS of 0.16 
[95% CI 0.04-0.64, P=0.001] while stage III patients had a HR of 0.70 [95% CI 0.44-1.09, P=0.04], 
which was statistically significant (33). 
MSI status may also be a predictive marker of treatment to 5-FU chemotherapy in stage II patients. 
This is primarily because the recurrence rate is considered too low to justify adjuvant chemotherapy 
in patients with MSI tumours (34). Additionally, some studies have indicated MSI tumours have a 
decreased benefit to adjuvant therapy (31, 35). In a retrospective analysis, stage II MSI patients who 
received chemotherapy did not experience an increased benefit compared to MSI patients who did 
not receive chemotherapy. However, MSS patients did see a benefit with the addition of 
chemotherapy (33). Further, no DFS benefit was detected with a trend towards worse outcomes in 
patients with MSI treated with Fluoropyrimidine monotherapy (33). This indicates 5-FU based 
chemotherapy may be detrimental to MSI tumours in stage II patients.  
The exploration of the underlying biology of MSI status further strengthens this association. MSI 
tumours often arise through disruption of the MLH1, PMS2, MSH2 or MSH6 genes which results in 
changes in pathological and molecular features not seen in MSS (36). The abundance of MSI-induced 
frameshift peptides are frequent targets of the immune system in MSI patients (36). Many of these 
responses have subsequently been shown to be mediated by tumour infiltrating lymphocytes (36). 
Furthermore, MSI tumour’s checkpoint proteins are upregulated compared to MSS tumours, which 
means they are less likely undergo immune evasion, an important hallmark of cancer progression 
(35). 
While MSI status appears to have powerful prognostic significance only 22% of stage II colon cancer 
patients have MSI tumours (21). This leaves a considerable number of patients with unpredictable 
treatment responses. Therefore, there is still a pressing need for more biomarkers like this to further 
stratify stage II patients and guide their treatment decisions. 
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Taken together, the success of this marker highlights two important points. Firstly, there is a great 
need for more biomarkers like MSI status in this population of patients. Secondly, MSI status 
highlights the factors necessary for clinically relevant biomarkers. As implied, this includes a strong 
association with prognosis that is independent of the TNM staging system and other 
clinicopathological risk factors, as well as the ability to predict outcome to treatment. Further, a 
clinically feasible way of detecting these markers is necessary. For example, dMMR can effectively 
be measured by IHC without the requirements of a molecular laboratory (29). Functional relevance 
of biomarkers to stage II colon cancer also provides confidence and can be used to form hypothesis 
for future drug targets. The effect of MSI on the surrounding tumour-microenvironment (TME) as 
described earlier, is clear, while for example gene-expression assays, developed through statistical 
approaches, do not provide any reassurance of their biological role (37). 
More recently, microRNAs and functional proteins associated with tumour-derived extracellular 
vesicles (tEVs) have emerged as potential biomarkers for stage II colon cancer patients. Their 
feasibility as a biomarker in the clinic and their functional relevance to stage II colon cancer patients 
makes them an attractive approach, as will be discussed. 
1.3 MIR-21, MIR-29A AND CD147 AS MOLECULAR BIOMARKERS IN CRC 
1.3.1 MIRNAS: DEFINITION AND FUNCTION IN CARCINOGENESIS 
MicroRNAs (miRNA) are small, non-coding, regulatory RNAs comprised of 21-24 nucleotides (38). 
They typically function by interacting with specific mRNAs through complementary base-pairing to 
influence the translation or stability of the target mRNA molecule (38). These RNA fragments are 
involved in many intracellular processes and remarkably, a single miRNA species is capable of 
binding and repressing multiple mRNA targets (38). As such miRNAs have been implicated in several 
biological and pathological processes, including carcinogenesis (38). The dysregulation of miRNAs in 
cancer cells has been found to influence a diverse range of intracellular pathways in cancer cells 
namely cell proliferation, apoptosis, differentiation and inflammation (39). For this reason, many 
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miRNAs have been termed “oncomiRs” or “tumour suppressive miRs” for their roles in 
carcinogenesis (39). 
1.3.2 MIRNA-21 AND MIR-29A AS BIOMARKERS IN COLORECTAL CANCER. 
Several aspects of tumour-associated miRNAs make them attractive as a new class of prognostic 
biomarkers in early-stage CRC. Most striking is their stability in biofluids partially due to their 
presence within membranous nano-micro sized particles called “tumour-derived extracellular-
vesicles” (tEVs) (40). Further, their aberrant expression profiles vary among difference tumour types 
making them specific to CRC (40). At least 37 different miRNA species have been found to be 
dysregulated in tumour tissue (41). Included among these are miR-21-5p (miR-21) and miR-29a-3p 
(miR-29a). Both are significantly upregulated in CRC tissue and in the blood of CRC patients (42, 43, 
44, 45). More importantly, studies over the last 10 years have gone on to find significant associations 
with these miRNAs and clinical risk factors, namely lymph node positivity and distant metastasis (41, 
44, 46). Subsequently, the functional role of miR-21 and miR-29a and their targets have been 
elucidated, further strengthening their potential as functional prognostic biomarkers in colorectal 
cancer (47, 48, 49). Despite this, the potential for these miRNAs as biomarkers in stage II colon 
cancer has been less well explored.  
miR-21 represents one of the most intensively studied oncomiRs due to its abundant overexpression 
in the vast majority of cancers including CRC (50). In CRC, miR-21 is arguably one of the most 
dysregulated miRNAs (41). One of miR-21’s most characterised roles is its ability to induce stable 
activation of PTEN, an important tumour suppressor. In turn, this stably induces the NFkb 
inflammatory pathway (47, 48) which is known to foster conditions to promote cancer progression, 
invasion and metastasis (51).  
Unsurprisingly, elevated miR-21 has consistently been associated with lymph node positivity, 
advanced TNM stage, poorly differentiated tumours and other clinical risk factors (41, 42, 46, 52) in 
populations consisting of all TNM stages. Furthermore, miR-21 is an independent predictor of DFS 
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(41, 46, 52). However, few studies have focused primarily on the prognostic impact of miR-21 in 
stage II CRC. Interestingly, miR-21 expression increases from early to late stage CRC and elevated 
levels have even been detected in adenomas (46). This suggests miR-21 overexpression could be an 
early event in progression of cancer making this miRNA particularly relevant to stage II colon cancer 
patients. 
Similarly, miR-29a is dysregulated in the majority of cancer types including CRC. Interestingly, this 
miRNA is downregulated in most cancer types (53) but significantly upregulated in tumour tissue and 
the blood of CRC patients (54) compared to healthy controls. This is consistent with its specific 
functional role in CRC where inhibition of E-cadherin, promotes epithelial-to-mesenchymal transition 
(EMT), thereby promoting cell invasion and metastasis (38). In contrast to miR-21, its prognostic 
potential has been less well explored in CRC tissue however, it is a well-known secretory miRNA that 
has both diagnostic and prognostic potential in the blood of CRC patients (44). Further, this marker 
has been associated with distant metastasis and poor OS (44). Taken together, miR-29 could also be 
an important prognostic tumour biomarker in stage II colon cancer.  
1.3.3 CD147 AS A BIOMARKER IN COLORECTAL CANCER 
In addition to miRNAs, protein markers are particularly important as they provide a more dynamic 
reflection of the impact of the cell’s genetic aberrations (55). CD147 is a transmembrane protein and 
like miR-21 and miR-29, it is released extracellularly in tEVs and plays an important role in tumour 
progression and aggressiveness (56). CD147/EMMPRIN (extracellular matrix metalloproteinase 
inducer), is best known for its role as a matrix metalloproteinase (MMP) inducer (57). MMPs are key 
mediators for extracellular matrix (ECM) and basement membrane degradation and therefore 
promoters of invasion and metastasis in cancer (57). More recently, CD147 has been shown to be 
involved in angiogenesis by enhancing VEGF levels in cancer cells and the mesenchyme (58), and 
other features such as hypoxia, anti-apoptosis and chemoresistance through a complex network of 
interactions (58, 59).  
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Notably CD147 has been detected in the vast majority of human cancer types including CRC (60) and 
is one of the most highly expressed proteins in disseminated cancer cells (61). Several publications 
have reported increased relative CD147 expression in CRC tumour compared to normal adjacent 
tissue and some have subsequently found associations with lymph node positivity, distant 
metastasis, as well as DFS (62, 63). Despite this, few studies have explored CD147 expression in stage 
II CRC alone. Those that have are small and variable in their outcomes with some reporting an 
association with cumulative survival and others failing to validate this (63, 64). This makes forming 
definitive conclusions difficult.  
1.4 SURROGATE MARKERS FOR EXTRACELLULAR VESICLES 
The functional relevance of potential biomarkers, including miR-21, miR-29a and CD147, may go 
beyond their expression in tumour tissue and be utilised in the tumour-draining lymph nodes 
(TDLNs) of stage II colon cancer patients. This is not in the context of detecting occult lymph node 
metastasis, however. Perhaps preliminary to this is the detection of tEVs.  
As mentioned, tEVs are bioactive, nano-micro sized particles, released from normal cells and tumour 
cells but in greater abundance (65). EVs are the generic term for many diverse, secreted vesicles 
including exosomes, microparticles and microvesicles (65). They are central to intercellular 
communication by carrying specific nucleic acids and proteins from their donor cell. They are 
abundant throughout the body, travelling through several bodily systems, including the lymphatics 
and blood and are capable of transferring molecular cargo to recipient neighbouring and distant cells 
(65). Consequently, tEVs have recently emerged as biomarkers and functional mediators of 
tumourigenesis in TDLNs and distant organs of cancer patients (65).  
One mechanism by which tEVs contribute to tumorigenesis is by formation of the pre-metastatic 
niche (PMN) in the draining lymph nodes (66). miR-21, miR-29a and CD147 have mostly been 
characterised as blood-based tEV markers however, their potential to detect tEVs in the lymph 
nodes is highly relevant to high-risk stage II colon cancer patients for two reasons: Firstly, the TDLNs 
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are typically the first place for dissemination of tumour cells (67) and secondly, detecting tEVs in 
surgically resected TDLNs is technically restricted. There is currently no standardised or validated 
methodology for isolating tEVs from human tissue samples let alone in a clinically feasible manner. 
Therefore, these markers could act both as biomarkers themselves and surrogate biomarkers for 
tEVs.  
1.4.1 TEVS AND THE PRE-METASTATIC NICHE (PMN) 
The PMN is a term relatively new to the field of metastatic research; however, it is thought to at 
least be partially responsible for metastatic formation (68). Intensive research efforts in animal 
models have discovered factors necessary for PNM formation including tumour-derived secretion 
factors (TDSFs) that are capable of conditioning distant sites in the body by regulating 
immunosuppression and hypoxia. This allows the recruitment and survival of metastatic cells within 
these sites (68). Along with TDSFs, tEVs are now emerging as potential mediators of PNM formation. 
Peinado et al (2016) demonstrated the mechanistic role for melanoma-derived EVs to condition the 
PMN (66). Using a mouse model, they demonstrated the ability for tEVs, isolated from metastatic 
melanoma cell lines, to educate bone marrow-derived cells (BMDCs). This promoted vascular 
leakiness, a hallmark of pre-metastatic formation, at pre-metastatic sites (66). While tEV-mediated 
PMN formation has not been investigated in CRC it has been demonstrated in animal models for 
breast, renal, pancreatic and other cancers (69, 70, 71). This suggests PNM formation could be a 
phenomenon in CRC.  
1.4.2 EVS AND CONDITIONING OF THE LYMPH NODES  
In CRC the TDLNs are the first place for dissemination of tumour cells (67) and lymph node 
metastasis is the most important prognostic factor differentiating stage II and III CRC (72). Therefore, 
certain molecular patterns and subsequent morphological changes in TDLNs of stage II patients may 
provide evidence of pre-metastatic spread (73, 74). tEVs present in the lymph nodes could be one of 
the first steps involved in metastatic spread to distant organs. Strikingly, melanoma-derived EVs 
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have been shown to support PNM formation in the lymph nodes by enhancing melanoma cell 
recruitment and potentially regulating the extracellular matrix and vascular proliferation (75) (Figure 
2). This animal study demonstrated the ability of melanoma EVs to home to sentinel lymph nodes 
and present molecular signals to influence the recruitment of melanoma cells as well as extracellular 
matrix deposition and vascular proliferation, ultimately facilitating metastatic spread (75). This fulfils 
the “seed and soil” hypothesis whereby the tEVs act as the “seed” and the lymph nodes the “soil” in 
preparation for metastasis (76) (Figure 2). Following up from this, Hu et al (2015) tracked melanoma 
EVs to specific regions of lymph nodes using MRI in vivo (77). Formation of PMN’s specifically in 
lymph nodes via tEVs has also been demonstrated in gastric, breast and ovarian cancer animal 
models (78, 79, 80) however, there is no such evidence in colon cancers. 
 
Figure 2: Melanoma-derived tEVs homing to lymph nodes  
A) Exosomes or tEVs shed from the primary melanoma and home to sentinel lymph nodes. B) 
Exosomes release molecular signals in the lymph nodes to change the extracellular matrix and 
promote angiogenesis. C) Exosomes promote the recruitment of melanoma cells to lymph nodes and 
support their deposition and growth through the changes made. From Hood et al 2011 (75). 
30 
 
1.4.3 LYMPH NODE TEVS AS PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS IN STAGE 
II COLON CANCER 
The prevalence of this phenomena across several types of cancers suggests it could be active in 
colon cancer. Extending from this, is the idea of using tEVs or surrogate markers within lymph nodes 
as prognostic and/or predictive biomarkers for clinical use. Stage II and III colon cancer are stratified 
based on the presence of tumour cells in the lymph nodes. Given tEVs direct site-specific metastasis 
through the lymph nodes, (81) detection of tEVs in the lymph nodes could be indicative of higher risk 
stage II disease. Compared to other emerging candidate biomarkers, where some are limited by lack 
of understanding of their mechanistic role, tEVs represent attractive biomarkers. This information 
could be used to add value to TNM staging and other clinical risk factors to more accurately stratify 
stage II patients. Additionally, they may have predictive value in terms of response to adjuvant 
chemotherapy, under the hypothesis that patients with micro-metastasis or early-stages of cancer 
spread might respond to this type of treatment. 
1.4.4 DETECTING TEVS IN LYMPH NODES USING SURROGATE BIOMARKERS  
One major limiting aspect of tEVs is their detection in humans. Their identification and 
characterisation remain a challenge in this field and any current techniques remain impractical in 
clinical settings (82). However, cancer-specific markers such as miR-21, miR-29a and CD147 are 
currently being used as surrogates for blood-based detection of tEVs in CRC patients. This was 
recently demonstrated by Yoshika and colleagues (2015) using antibodies against CD147 in the blood 
of CRC patients. They found this simple method could be used to detect CD147 positive tEVs (56). 
Likewise, Tsukamoto and colleagues (2017) detected miR-21 through exosomal plasma in CRC 
patients finding significant correlations with tissue levels as well as associations with clinical factors 
(83). This was achieved through microarray analyses in exosomal plasma.  
CD147 is detectable in the invaded lymph nodes of CRC patients using IHC in formalin-fixed paraffin 
embedded (FFPE) samples (62, 63). As mentioned previously, this method is also used on tumour 
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samples for the clinical detection of MSI. Furthermore, miRNA can now be extracted from FFPE 
samples and subsequently quantified by quantitative reverse transcription PCR (RT-qPCR) (84). 
Therefore, it seems plausible and clinically appropriate that tEVs present in the draining lymph 
nodes could be detected through IHC and RT-qPCR techniques in FFPE samples, after surgical 
resection. This would also avoid compromising pathological assessment of these lymph nodes for 
diagnostic confirmation of the disease. 
miR-21, miR-29a, CD147 or any tumour-specific biomarker encapsulated in tEVs in the lymph nodes 
of stage II colon cancer patients has not been investigated to date but is certainly an interesting 
research question. In contrast to other candidate biomarkers, in particular, gene-expression 
profiling, these markers along with tEVs may have a clearer functional role. This is particularly 
pertinent to early-stage colon cancer where patients typically do not undergo neo-adjuvant therapy, 
which is known to disrupt the morphology of lymph nodes in rectal cancer patients (85).  
The detection of miR-21, miR-29a and CD147 in the tumour and lymph nodes of stage II patients 
could provide additional prognostic power. Success in this area may pave the way for more accurate 
stratifying of patients in the clinic, which would significantly improve the health outcomes of many 
New Zealanders. Stage II colon cancer patients are clinically heterogenous and therefore 
stratification and subsequent treatment of these patients is a challenge. MSI status is currently the 
only successful biomarker that aids in decision making for treatment of these patients and paves the 
way for more biomarkers to be used in the clinic. Analogous to MSI status, miR-21, miR-29a, and 
CD147 may have a clear, functional role in tumour biology. Specifically, these markers are involved in 
the initiation and progression of CRC. Further their association with tEVs, which are involved in 
priming the lymph nodes for metastatic spread, make these markers particularly relevant for 
detecting high-risk stage II colon cancer patients. Lastly, detection of these biomarkers, both on their 
own and as surrogates for tEVs, through IHC and RT-qPCR in FFPE samples, allows for their ease of 
translation into clinical practice. 
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1.5 AIMS AND OBJECTIVES  
There is an apparent need for more prognostic and predictive biomarkers to improve the risk 
assessment and adjuvant chemotherapeutic strategies in stage II colon cancer patients. The 
necessary factors for a clinically successful biomarker include: A prognostic and/or predictive impact 
that is more informative than current clinicopathological risk-factors and a clinically feasible way of 
measuring the marker. Further, functional relevance to the specific populations can support the use 
of biomarkers. miR-21, miR-29a and CD147 have recently emerged as potential biomarkers in CRC. 
Due to their functionality in the initiation and development of CRC and their association with tEVs 
we hypothesise these markers could provide important prognostic information for stage II colon 
cancer patients.  
The overall aim of this exploratory pilot study was to characterise the expression of potential 
biomarkers: miR-21, miR-29a and CD147 in the tumour and draining lymph nodes in a small pilot 
cohort of stage II colon cancer patients. The use of antibodies specific for CD147 in FFPE samples 
represents a simple, sensitive and clinically relevant approach. Further, molecular technologies, such 
as RT-qPCR, provide a strong quantitative tool with a high level of precision and reproducibility to 
detect small differences in expression levels of miRNAs (86). The specific objectives of the study 
were as follows; 
1) To establish and optimise the molecular techniques necessary to detect miR-21, miR-29a and 
CD147 in the tumours, normal mucosa tissues and TDLNs of stage II colon cancer patients. 
Optimisation of IHC for the detection of CD147 and RT-qPCR for the detection of miR-21 and miR-
29a was performed in formalin-fixed tissues and/or specimens preserved in RNAlater. 
2) To begin to characterise the expression levels of these markers in tumour and normal mucosa in a 
small pilot cohort of stage II colon cancer patients. This was to determine whether these markers 
were dysregulated in the tumours and to what extent. Further, to explore the prognostic significance 
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of these markers we compared the expression status of these markers to certain pathological risk 
features in the cohort.  
3) To explore the expression levels of these markers in the TDLNs in the cohort. This was to 
determine if tumour-associated expression of these markers was present in the TDLNs and could be 
indicators of pre-metastatic spread. 
We hypothesised that cancer-associated miR-21, miR-29a and CD147 expression levels would be 
measurable in the tumours and TDLNs of stage II colon cancer patients. Further, we believed 
expression differences between tumour and normal mucosa tissue samples would be detectable.   
The results of this pilot study will allow us to understand whether CD147, miR-21 and miR-29a have 
any prognostic utility in stage II colon cancer patients, form hypotheses and determine whether the 
detection of these markers is clinically feasible. Further, the results will determine whether tumour-
associated expression is present in the TDLNs of these patients and has any prognostic potential. 
Ultimately, this study will inform larger, future prospective cohorts which will validate the prognostic 
significance of these markers to determine whether they are more informative than current 








CHAPTER 2: MATERIALS AND METHODS 
2.1 ETHICAL CONSIDERATIONS AND CASE SELECTION 
2.1.1 ETHICS APPROVAL AND CONSENT TO PARTICIPATE 
At the beginning of the study period, the primary researcher selected patients (to be in the current 
study) from the web-based application Research Electronic Data Capture (REDCap), a database for 
the Surgical Cancer Research Group (SCRG) Colorectal Cancer Biobank. This multi-disciplinary 
research group collects and stores blood and tissue samples from CRC patients at Wellington 
Hospital who have consented to be a part of “genetic and molecular research”. Patient 
demographics and clinicopathological features are also collected prospectively from hospital records 
and stored within the REDcap database. Informed consent to collect tissue samples for banking and 
future, unspecified research was obtained from each participant. Ethical approval for this biobank 
and the current study was obtained from the Central Health Ethics Committee (15/CEN/143).  
2.2.2 ETHICAL CONSIDERATIONS 
Because the patients had already consented into being a part of the biobank, this altered the ethical 
considerations of the current study. However, it was essential that the primary researcher was 
aware of some aspects that were outlined during the recruitment process. For example, the 
voluntary nature of participation, which means patients are free to withdraw from the study at any 
time. Further, the researcher had access to a secure database that contained specific patient details. 
Therefore, it was a requirement of the researcher to adhere to de-identification and the 
confidentiality of these patients. 
2.2.2 TE ARA TIKA 
It was also important that the primary researcher was cognisant of the ethical considerations 
surrounding Māori participation. Respect for and incorporation of Tikanga was paramount. For 
example, Te Whakahoki i te Taonga (return of the gift) which refers to providing access for donors to 
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research reports and raw data when requested, was discussed at the time of recruitment. Further, 
disposal of tissues by a karakia (blessing) was offered at the time of recruitment and if chosen, 
adhered to. Specifically, the author of this study treated all samples with respect during the research 
protocols and kept in mind at all times the importance tikanga.  
2.2.3 CASE SELECTION AND SAMPLE COLLECTION 
A search strategy was applied based on the following inclusion/exclusion criteria: TNM stage II colon 
adenocarcinomas (5), excluding those within the rectosigmoid junction and patients that have 
received neo-adjuvant therapy. Patients with a previous history of malignancies or inflammatory 
bowel conditions were also excluded. Of note, the biobank excludes patients with emergency 
presentations due the time constraints and ethical considerations of obtaining informed consent in a 
short time frame.  
The same search strategy was applied but with the inclusion of stage III patients for a positive 
control. The database was further searched for a negative control patient with surgically resected 
lymph nodes of the colon, who previously had a high suspicion of cancer, (and therefore falls under 
the ethical requirements of this study) but was found to be negative for cancer.  
Available colonic tumour and normal mucosa samples of selected patients were collected from the 
biobank of surgical samples. Samples frozen in RNAlater or fixed in 4% paraformaldehyde (PFA) were 
collected. The FFPE TDLN’s were also collected for the corresponding patients after pathological 
assessment.  
2.2.4 PATIENT CLINICOPATHOLOGICAL CHARACTERISTICS  
Patient demographics were collected from the REDCap database. This included; age, gender and 
ethnicity. Selected clinicopathological characteristic were also collected. This included; T staging, 
tumour cell type, grade, CEA level, extramural vascular invasion, perineural invasion, lymphatic 
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invasion, presence of multiple polyps, dMMR status and the number of lymph nodes surgically 
resected.   
2.2 IMMUNOHISTOCHEMICAL DETECTION OF CD147 
2.2.1 PARAFFIN PROCESSING OF TISSUE  
Tumour and normal mucosa samples that were previously fixed in 4% PFA for 16-24 hours were 
prepared for paraffin infiltration using the Sakura Tissue Tek Processor overnight in cassettes. 
Briefly, tissues were dehydrated through a series of graded ethanol baths to displace water and then 
infiltrated with paraffin wax.  
Specifically, tissue was processed as follows:  
• Dehydration in 70% ethanol (etoh), 1-hour (hr) 
• 95% etoh, 1-hr 
• 100% etoh, 1-hr 
• 100% etoh, 11/2-hrs 
• 100% etoh, 11/2-hrs 
• 100% etoh, 2-hrs 
• Xylene (clearing agent), 1-hr 
• Xylene, 1-hr 
• First paraffin wax, 1-hr 
• Second paraffin wax, 1-hr 
Tissues processed into paraffin were then embedded into smooth paraffin blocks using the Sakura 
Tissue Tek Embedding Centre. Tissues were placed in a 58◦C paraffin bath for 15 minutes to melt 
surface wax away. A mold was chosen that best corresponded with the size of the tissue. Tissue was 
placed into the mold (cut side placed face down) and molten paraffin was subsequently dispensed 
into the mold. The mold was transferred to a cold plate to allow paraffin to solidify and hold tissue in 
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the desired orientation. The labelled tissue cassette was placed on top of the mold as the backing. 
More molten paraffin was added to cover the face of the plastic cassette. Paraffin blocks were 
allowed to solidify on ice for 30 minutes. The paraffin block was then popped out of the mold and 
the tissue was checked for any cracks or air bubbles. If artefacts were present, the blocks were 
melted and re-embedded in paraffin.  
2.2.2 SECTIONING TISSUES FOR REPRESENTATIVE H&E SLIDES  
Tissue blocks were sectioned using the Sakura Tissue Tek microtome. In preparation, tissue blocks 
were placed face down on ice for 10 minutes. Blocks were then sectioned at 4µM. Sections laid on 
top of a 37◦C water bath to de-wrinkle sections and subsequently picked up on adhesive/positively 
charged slides. Slides were then allowed to air dry for at least 1 hour and then incubated at 60◦C for 
1 hour until paraffin was transparent.  
Sections were stained with Haemotoxylin and Eosin (H&E) as follows: 
• Dewaxed in xylene, 3x 5-minute washes (min) 
• Rehydration in 100% etoh, 2x 5-min 
• 95% etoh, 2x 5-min 
• 80% etoh, 2x 5-min 
• 70% etoh, 2x 5-min 
• Tap water, 2x 5-min 
• Harris’ Haemotoxylin,10mins 
• Tap water, 20 seconds (sec) 
• 1% Acid alcohol, 5-sec 
• Scotts tap water, 2-min,  
• Eosin, 2-min  
• Tap water, 20-sec.  
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• Rinsed in distilled water 
Slides were then blotted dry around the sections. DPX mounting media was distributed evenly over 
the tissue and slides were coverslipped.   
2.2.3 TMA CONSTRUCTION 
Tumour, normal mucosa and lymph node FFPE samples from all patients that were available were 
represented in 7x Unitma pre-made tissue microarray (TMA) blocks as 3mm diameter cores using 
the Quick-RayTM Manual Tissue Microarrayer (figure 3). Representative areas from the donor blocks 
were chosen based on the density of tissue (using the H&E reference slides) (figure 3). TMA recipient 
blocks were then incubated at 60ᵒC for 45 minutes (or until transparent) in an embedding mold. 
Paraffin was poured over the TMA block and solidified to a cassette on a cold plate. 4µm sections 
were cut and transferred to adhesive-coated slides using a 47ᵒC and 55ᵒC water bath respectively. 












Figure 3: Tissue Microarray construction  
3mm cores were extracted from the densest area of donor tissue blocks (tumour, normal mucosa and 
lymph node samples), using the reference H&E sections. Cores were then punctured and organised 
into recipient tissue microarray (TMA) blocks. Typically, each block contained a tumour, normal 
mucosa sample and corresponding lymph nodes for each patient. 4µM sections were cut from the 








2.2.4 CD147 IMMUNOHISTOCHEMISTRY 
The expression of CD147 was analysed by IHC staining of the TMA sections. The following methods 
were based off recommendations from the Manufacturers protocol (Novus Biologicals). Sections 
were deparaffinised and rehydrated as follows: 
• Xylene 3x 5-min 
• Rehydration in 100% etoh, 2x 10-min  
• 95% etoh, 2x 10-min 
• 70% etoh, 2x 10-min 
• 50% etoh, 2x 10-min  
• Deionized water, 2x 5-minute 
Antigen retrieval was trialled using both a microwave and pressure cooker method. Spare sections 
were placed in 1mM EDTA and 0.05% Tween solution (pH 8.0) and either microwaved for 3x 5-min 
bursts or placed in the pressure cooker on high for 5-min. After optimisation, all samples were 
placed in antigen retrieval solution in the pressure cooker on high for 5 minutes. Sections were 
cooled to room temperature in antigen retrieval solution.  
R&D Systems Goat VisUCyteTM HRP Polymer-DAB Cell & Tissue Staining Kit for detection of goat IgG 
Antibodies was used in combination with R&D Systems Human EMMPRIN/CD147 Affinity Purified 
Polyclonal Antibody (Ab). The manufacturers protocol was followed for the blocking, IHC and 
chromogenic staining procedure. Conditions for the primary Ab were optimised using spare TMA 
sections. 3 different concentrations were trialled: 1, 0.5 and 0.2 μg/ml. In the final optimised 
protocol all TMA sections were stained at 0.5 μg/ml for 1 hour at room temperature on 2 separate 
occasions. PBS controls for each TMA were also included.  
All TMA sections were counterstained with Haematoxylin as follows: 
• Water 5-min  
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• Haematoxylin ‘dips’ 
• Tap water gently ‘dippping’, 30-sec 
• Dehydrated in 75% etoh, 1-min 
• 90% etoh, 1-min 
• 100% etoh, 1-min  
• Xylene 2x 1-min washes 
Sections were then air dried and coverslipped with DPX mounting media as described earlier. 
4x, 10x and 20x field of view images for each sample within the stained TMA sections were taken 
using a confocal microscope. Evaluation of staining intensity was performed while blinded to cohort 
and clinicopathological characteristics. Evaluation was strictly qualitative and a modified version of a 
previously described scoring system (62). A score of 0 indicates no difference, 1 indicates a moderate 
increase and 2 indicates a high increase in staining of the tumour compared to normal mucosa. 
Tumours with a score of 1-2 were considered positive and a score of 0 was considered negative for 
CD147 overexpression. 
2.3 MIRNA ANALYSIS  
2.3.1 TOTAL RNA EXTRACTION FROM FFPE LYMPH NODE CORES  
During TMA construction, additional 3mm cores were taken from the same FFPE lymph nodes and 
frozen at -20ᵒC until use. Cores were then deparaffinised in xylene and washed with 100% ethanol 
twice. Homogenisation of spare cores was trialled using a mortar and pestle in 100% ethanol 
however, this proved inefficient and instead the cores were homogenised in 100% ethanol using a 
hand-operated motor driven grinder. Total RNA was prepared from the cores using the Qiagen 




2.3.2 TOTAL RNA EXTRACTION FROM TISSUES STORED IN RNALATER 
Corresponding tumour and normal mucosa samples stored at -20ᵒC in RNAlater solution (non-toxic 
reagent stabilises and protects cellular RNA) were collected and 50mg of tissue was cut from the 
original samples. Samples were washed in PBS 3x and minced using surgical blades to assist the 
homogenisation process. The minced tissue was homogenised in QIAzole Lysis Reagent using a hand-
operated motor driven grinder. Total RNA was prepared from the samples using the Qiagen 
miRNeasy kit following the manufacturer’s protocol. Total RNA was quantified using the Nanodrop 
spectrophotometer.  
2.3.3 CDNA SYNTHESIS 
10µg of total RNA from the tumour and normal tissue of patient samples that were available was 
used to synthesise double-stranded cDNA. Additionally, total RNA from 23 randomly selected lymph 
nodes across all patients were used to synthesise cDNA. The TaqMan Advanced miRNA cDNA 
Synthesis Kit (Applied Biosystems) was used for this purpose following the manufactures protocol.  
2.3.4 QUANTITATIVE REAL-TIME PCR-BASED DETECTION OF MIR-21 AND MIR-29A 
miRNA expression of hsa-miR-21-5p, hsa-miR-29a-3p, hsa-miR-345-5p and hsa-miR-16-5p was 
examined by real-time PCR using the TaqManTM Fast Advanced Master Mix, miRNA assays (Applied 
Biosystems) and the RotorGene 6000 detection system. The manufacturers protocol for detection 
was followed.  
miRNA was measured using threshold cycle values (Ct). The threshold was set at 0.06529 during the 
log phase of replication for each run (figure 4). Each sample was run in duplicate to obtain 2 Ct 
values. Duplicate Ct values were less than 0.5 units apart (figure 4). Averaged Ct values of miR-345 
and miR-16 were used to normalise miR-21 and miR-29a average Ct values. The fold change for each 




Figure 4:Representative RT-qPCR amplification curves for miR-21, miR-29a and miR-345 in a 
tumour sample, performed in duplicates.  
Threshold bar set at 0.06529 to obtain threshold cycle values. 
2.4 HISTOMORPHOLOGICAL ANALYSIS  
The following evaluation procedure was based on previous methodology (73).  Morphometrical 
analysis was performed on 4x (field of view) lymph node images stained for CD147 (figure 5). All 
lymph nodes compartments were annotated using ImageJ software (ImageJ 1.52a Wayne Rasban, 
National Institutes of Health, USA). Specifically, germinal centres (GCs) (characterised by CD147 
(brown) staining), follicles (characterised by an intense blue ring around the GCs) and primary 
follicles (intense blue compartments with no GCs) were quantified (figure 5). Follicle and GC density, 
were calculated as the average number of follicles/GCs per lymph node and follicle and GC size were 
calculated by averaging the circumference of the 3 largest follicles/GCs in each LN. Further, primary 
follicle density was calculated as the average number of follicles minus the average number of GCs 




















Figure 5:Evaluation procedure for lymph node histomorphological analysis  
Left: All lymph nodes were annotated for B cell compartments (red and yellow dashed lines) using 
ImageJ. (I) Circular Germinal centre (GCs), (II) Non-circular/fused GC, (III) follicle. Right: Calculations 
for follicle and GC density (number of follicles/GCs per lymph node), follicle and GC size and primary 
follicle density (number of primary follicles per lymph node).  
2.4 ASSOCIATIONS WITH PATHOLOGICAL FEATURES 
miR-21, miR-29a and CD147 tumour expression levels were compared to certain pathological risk 
factors. While OS and DFS are considered gold-standard endpoints (89) in investigations of 
prognostic biomarkers, it was not possible to examine these end points as the mean follow-up 
period since the time of surgery was 8 months (table 3). While DFS at 3 years is considered 
appropriate for assessing prognosis in colon cancer patients, OS at 5 years is the most quoted metric 
for this purpose (89). Current pathological risk factors used in stage II colon cancer patients are not 
completely accurate (14) however, correlations of potential biomarkers with these factors could be 
used to form hypotheses regarding the prognostic utility of these biomarkers. 
The risk factors considered included moderate-poor tumour differentiation grade, T4 tumours (size 
or extent of the primary tumour), presence of multiple polyps, mucinous tumour type, lymphatic 
invasion, perineural invasion and extramural vascular invasion. All have been associated with a 
worse prognosis in stage II colon cancer patients and are recognised as risk-factors by several expert 
        Annotations                                                                       Calculations                                                 
Follicle and GC density = average # of follicles/GCs 
per LN 
Follicle and GC size = average circumference of the 
3 largest follicles/GCs per LN 
Primary follicle density = average # of follicles – 







panels including ASCO and ESMO (12, 13). However, due to a small cohort size, only tumour grade, T 
stage and lymphatic invasion were compared to expression levels of miR-21 and miR-29a. Of note, 
CD147 was not considered in any comparisons due to a small sample size. For the lymph node 
morphological features follicle and GC density and size were compared to tumour grade, T stage, 
lymphatic invasion and dMMR status. 
2.5 STATISTICAL ANALYSIS  
For descriptive statistics and statistical testing, GraphPad Prism software (GraphPad Prism 7.00 
software, Inc) was used. For comparisons between tumour and normal mucosa one-sided paired 
testing was used because it was a within-subject comparison and data was normally distributed. 
While unpaired testing was used for comparisons between two independent groups. Appropriate 
adjustments were made when data was not normally distributed or standard deviations were not 
equal using Mann-Whitney, Welch’s and Wilcoxon t-tests. It must be noted however, that due to the 
















CHAPTER 3: RESULTS  
 3.1 COHORT CHARACTERISTICS 
 
Based on the inclusion/exclusion criteria applied to the REDCap database of the SCRG CRC Biobank, 
13 cases of TNM stage II and 6 cases of TNM stage III colon adenocarcinomas were available from 
the report output. A stage III patient was chosen as a positive control that closely matched the 
median age of all 13 stage II patients and where surgical samples were available. Further, a patient 
with diverticulosis (previous high suspicion of CRC) was chosen as a negative control.   
Frozen and formalin-fixed tumour and normal mucosa samples were available for 10 stage II patients 
and for the stage III positive control. Further, FFPE TDLNs were available for all stage II patients, the 
stage III patient and mesenteric FFPE lymph nodes from the non-cancer patient (negative control).  
A detailed listing of cohort and clinicopathological characteristics of all cancer patients in the study 
are listed in table 3. Of the entire patient cohort (n=14), age at the time of diagnosis was 67 years (± 
14), with an even number of males to females. The cohort was predominately European (n=13) with 
one Māori patient. This closely resembles the incidence of CRC in Māori in New Zealand which is 
approximately 6% (2).  
Of the selected tumour characteristics and risk factors, all tumours were adenocarcinomas with only 
2 cases being mucinous adenocarcinomas. As expected, majority of the tumours were T3 stage (n=9) 
and had well differentiated pathology (n=9) with few patients having T4a/b tumours (n=5) and 
moderate to poorly differentiated tumours (n=5). The presence of extramural vascular, perineural or 
lymphatic invasion was only present in the stage III patient and 5 stage II patients. 3 stage II patients 
had evidence of multiple polyps along with the primary tumour. 3.5ng/ml was chosen as the cut-off 
value for the preoperative CEA (private communication). 8 patients had a CEA value more than 




Of note, perforation and obstruction are also considered risk factors however, the biobank excludes 






























Table 3: Cohort and tumour clinicopathological characteristics  
Characteristic 
N (%) Median (range) 
Cases  14  
Agea    7 (50) 67 ± 14 (34-78) 
Gender Male 7 (50)  
 Female 7 (50)  
Ethnicity  European 13 (93)  
 Māori 1 (7)  
Stage  II 13 (93)  
 III 1 (7)  
T stage T3 9 (64.3)  
 T4a 3 (21.3)  
 T4b 2 (14.3)  
Cell type Adenocarcinoma 12 (86)  
 
Mucinous 
adenocarcinoma 2 (14)  
Grade Well differentiated 9 (64)  
 
Moderately 
differentiated 1 (7)  
 
Poorly 
differentiated 4 (29)  
CEAb <3.5 6 (43) 1.95 ± 0.5707 (1.1-2.4) 
 ≥3.5 8 (57) 6.5 ± 11.62 (5.5-32.4) 
Extramural vascular Invasion Yes 2 (7)  
 No 12 (86)  
Perineural Invasion Yes 2 (7)  
 No 12 (86)  
Lymphatic Invasion Yes 5 (36)  
 No 9 (64)  
Multiple Polyps Yes 4 (29)  
 No 10 (7)  
MMR deficiencyc Not tested 3 (21)  
 No evidence 6 (43)  
 Evidence 5 (36)  
Lymph nodes examinedd  ≥12 13 (93) 21 (5-39) 
 <12 1 (7)  
Follow-up period since surgery 
(months)   8 (3-15) 
aThe median was used for the age cut-off value 
bCEA level 3.5ng/ml cut-off (private communication) 
cDeficiency in at least one of MSH2, MSH6, PMS2, MLH1 







3.2 OPTIMISATION OF TECHNIQUES FOR THE DETECTION OF CD147 
To characterise the expression levels and distribution of CD147 in stage II colon tumour samples 
using a clinically feasible approach, IHC was applied to 10 pairs of colon cancer and normal mucosa 
formalin-fixed tissues. This required establishment and optimisation of this technique to the 
specified tissues.  
3.2.1 ANTIGEN (OR EPITOPE) RETRIEVAL 
Two heat-induced antigen retrieval methods were used to reverse fixation-dependent protein 
crosslinking and masking of antigenic sites. Both a microwave and pressure cooker were trialled to 
determine the best technique for antigen retrieval. The microwave method was deemed 
inappropriate due to uneven staining of the top half of the sections compared to the bottom half, 
suggesting uneven antigen retrieval (figure 6). The pressure cooker method produced more 







































Figure 6: CD147 staining using the microwave and pressure cooker method of antigen retrieval. 
A) Overstained normal mucosa and tumour tissue using microwave method. B) Under stained normal 
mucosa and tumour tissue using microwave method. C) Consistent staining of normal mucosa and 
tumour using the pressure cooker method. 
3.2.2 PRIMARY ANTIBODY CONDITIONS FOR TMA SECTIONS 
To visualise specific CD147 staining while minimizing non-specific background signals the 
appropriate conditions for the primary antibody were determined by trialling 3 different 
concentrations at a single exposure time of 1 hour. The antibody was trialled against TMA sections 
containing stage III and II tumours, normal mucosa and lymph node samples at time 1, 0.5 and 0.2 
μg/ml for 1 hour at room temperature (figure 7) along with PBS controls. These conditions were 










0.5μg/ml appeared to be the most appropriate, showing less background staining, greater 
membrane localisation signal and sufficient intensity of staining compared to 1μg/ml and 0.2μg/ml 
in both tumour and normal mucosa tissues (figure 7). Further, low to moderate intensity of staining 
was still observed in the normal mucosa tissue at 0.5μg/ml, which is representative of physiological 
levels of CD147 in the colon. Despite this, intensity of staining in tumour tissues was visually 
distinguishable to normal mucosa tissue (figure 7C). Therefore, tumour tissues with overexpression 




















Figure 7: Primary antibody concentration optimisation for IHC detection of CD147 
A) No difference between normal mucosa and tumour CD147 staining and haematoxylin cannot be 
seen using 1 µg/ml primary antibody. B) Greater intensity of CD147 staining in tumour compared to 
normal mucosa and haematoxylin provides contrast using 0.5 µg/ml. C) No CD147 staining visible in 
normal mucosa or tumour using 0.2 µg/m of primary antibody. Scale bar=250 µM. 










3.3 OPTIMISATION AND QUALITY CONTROL OF TECHNIQUES FOR THE 
DETECTION OF MIR-21 AND MIR-29A 
3.3.1 HOMOGENISATION TECHNIQUES FOR THE PREPARATION OF NORMAL MUCOSA, 
TUMOUR AND LYMPH NODE TISSUE 
Initially, mechanical disruption with a mortar and pestle was trialled against tissue samples. 
However, this process proved inefficient with large chunks of tissue still present after 10 minutes of 
grinding action. Instead, a motorized mortar and pestle homogeniser was trialled which successfully 
homogenised all tissue types, although tumour and normal mucosa tissues required additional 
mechanical mincing using surgical blades prior to homogenisation. Sufficient RNA yields and sample 
purity were gained for all tissue types (table 4). At least 10ng/µl were required for downstream 
miRNA quantification (TaqMan applied biosystems). Only RNA with a ratio of absorbance at 260 and 
280nm (A260/280) between 1.6 and 2.2 were used (Qiagen RNeasy kit).  
Table 4: Representative RNA yields (ng/µl) and ratio of absorbance at 260 and 280nm (A260/280) 
from tumour, normal mucosa and lymph node samples. 
Tumour Normal Mucosa Lymph node 
RNA (ng/µl) A260/280 RNA (ng/µl) A260/280 RNA (ng/µl) A260/280 
1093.5 2.10 164.3 2.06 2518.5 1.99 
790.5 2.09 575.5 2.08 967.4 2.02 
670.6 2.08 195.9 2.05 598 1.96 
692.3 2.10 82.3 2.00 1485 1.96 
1075.9 2.09 98.1 2.06 1246.5 1.94 
1307.7 2.09 1239.9 2.07 369.5 1.96 
728.9 2.09 1501.5 2.09 1467.8 2.03 
1260.3 2.08 808.3 2.08 107.4 1.96 
446.1 2.06 226.1 2.06 1286.7 1.99 




3.3.2 EVALUATION OF ENDOGENOUS CONTROL (REFERENCE) MIRNAS FOR NORMAL 
MUCOSA, TUMOUR AND LYMPH NODE TISSUE 
miR-345 and miR-16 were trialled as endogenous controls for normalisation of miR-21 and miR-29a 
RT-qPCR in tumour and normal mucosa tissue and/or the lymph nodes (figure 8). For tumour and 
normal mucosa tissues, Ct values of miR-345 and miR-16 were all within 2 Ct values and no statistical 
differences in terms of mean Ct values and standard deviations were detected between normal 
mucosa and tumour samples (figure A, B). Therefore, the geometric mean of the two miRNAs was 
used to normalise tumour and normal mucosa samples (figure 8C). Again, no statistical differences 
were detected between normal mucosa and tumour samples. 
Mean Ct values and standard deviations between the non-cancer (negative control) and stage II 
lymph nodes were not statistically different for both miR-345 and miR-16 (figure D, E). However, a 
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Figure 8: RT-qPCR Ct values of miR-345 and miR-16 endogenous controls for tumour, normal 
mucosa and lymph node tissues. 
A, B and E) No differences were observed between normal mucosa and tumour tissue for Ct values of 
miR-345, miR-16 or the geometric mean. All samples were within 2 Ct values. C, D and F) No 
differences were observed between the non-cancer and stage II lymph nodes for Ct values of miR-345 
and miR-16. However, a large range of Ct values were observed in both groups for miR-345 (24.75-






3.4 CHARACTERISATION OF CD147, MIR-21 AND MIR-29A IN STAGE II TUMOURS  
3.4.1 IMMUNOHISTOCHEMICAL CHARACTERISATION OF CD147 IN STAGE II COLON 
CANCER TUMOURS 
After optimisation of IHC to stage II and III TMA sections, the protocol was applied to 10 patient 
tumour and normal mucosa samples available as 3mm cores within recipient TMA blocks. The 
protocol was also performed on PBS controls (no primary antibody) and repeated on a separate 
occasion.  
CD147 immunostaining was both membranous in tumour cells and the intestinal glands of normal 
mucosa tissues (figure 9). CD147 was abundant in both tumour and normal mucosa tissues however, 
intensity of staining was generally lower in normal mucosa tissues. The overexpression of CD147 
protein in each tumour was qualitatively evaluated based on the intensity of staining relative to the 
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Figure 9: Qualitative IHC evaluation of staining intensity for CD147 in paired stage III (positive 
control) and stage II tumour and normal mucosa tissues. 
Intensity score of 0= no difference in staining intensity between paired tumour and normal mucosa, 
1= Moderate increase in staining intensity of tumour compared to matched normal mucosa, 2= High 









3.4.2 TUMOUR CD147 EXPRESSION AND PATHOLOGICAL RISK FACTORS  
The number of patients in the present study was too small to compare CD147 status and 
pathological factors such as T stage, pathological differentiation and lymphatic invasion. However, of 
note is the absence of patients with both a low CD147 expression and T4a/b stage (table 5). 
Table 5: T stage, tumour grade and lymphatic invasion verse CD147 expression in stage II colon 
tumours 
Pathological 
feature           CD147 overexpression 
 Positive n (%) Negative n (%) 
T3 3 (42.86) 4 (57.14) 
T4a/b 3 (100) 0 (0) 
Low grade 4 (66.67) 2 (33.33) 
High grade 2 (50) 2 (50) 
Lymph invasion 2 (50) 2 (50) 
None 4 (66.67) 2 (33.33) 
 
3.4.3 CHARACTERISATION OF MIR-21 AND MIR-29A IN STAGE II COLON CANCER 
TUMOURS USING QUANTITATIVE RT-PCR 
To characterise and quantify the expression levels of miR-21 and miR-29a in stage II colon tumours, 
quantitative reverse-transcription PCR (RT-qPCR) was applied to the same tumour and normal 
mucosa pairs.  
miR-21 was upregulated in 50% of tumours compared to normal mucosa samples (figure 10A). 
Higher miR-21 relative expression levels were observed in the tumour samples (1.631 ± 1.029) 
compared to normal mucosa samples (1.045 ± 0.3358). This association did not reach statistical 
significance, but a trend was observed (p=0.071).  
Greater variability was also observed for the tumours compared to normal mucosa samples (figure 
10A). There was a statistically significant difference (p=0.0027) between the standard deviations of 
the tumours and the normal mucosa samples. 
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miR-29a was upregulated in the tumour of 1 patient and downregulated in the tumours of 8 patients 
compared to normal mucosa samples (figure 10B). Overall lower miR-29a relative expression levels 
were observed in the tumour samples (0.8894 ± 0.6428) compared to the normal mucosa samples 
(1.054 ± 0.3378). However, this association did not reach statistical significance, but a trend towards 
statistical significance was observed (p=0.0967). No difference in variability was observed between 
the tumours compared to normal mucosa samples. 
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Figure 10: Relative expression of miR-21 and miR-29a in matched tumour and normal mucosa 
sample of stage II colon tumours. 
A) miR-21 relative expression normal mucosa verse tumour (p=0.071, paired t-test). B) miR-29 
relative expression normal mucosa verse tumour (p=0.0967, Wilcoxon t-test). 
3.4.4 TUMOUR MIR-21, MIR-29A EXPRESSION LEVELS AND PATHOLOGICAL RISK 
FACTORS 
Due to a small cohort size, only tumour grade, T stage and lymphatic invasion pathological factors 
were compared to expression levels of miR-21 and miR-29a (figure 11).  
Lower miR-21 relative expression levels were observed in patients with a high T stage (T4a/b) 
(0.7634 ± 0.1313) compared to patients with a low T stage (T3) (1.615 ± 0.3214) (figure 11A). This 
association trended towards statistical significance (p=0.0681). Further, patients with low grade 
tumours had significantly lower miR-29a relative expression levels (median=0.5833) compared to 
high grade tumours (median=0.959) (p=0.0048) (figure 11F). No other trends or associations were 
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Figure 11: Tumour miR-21, miR-29a relative expression and pathological factors. 
A) miR-21 relative expression in T3 verse T4a/b tumours (p=0.0681, unpaired t-test). F) miR-29a 
relative expression in low grade verse high grade tumours (p=0.0048, Mann-Whitney t-test). B, C, D, 
E) No other trends or associations were found between miR-21, miR-29a and T stage, lymphatic 
invasion and tumour grade. ** = p value < 0.01.  
3.4.5 Association between miR-21, miR-29a and CD147 tumour  LEVELS   
The expression levels of CD147, miR-21 and miR-29a were compared to determine if there was a 
relationship between the markers (figure 12).  
Tumours with positive CD147 protein levels had lower miR-21 relative expression levels (1.01 ± 







association was statistically significant (p=0.0481). Interestingly, all patients with positive CD147 
tumours had low tumour expression of miR-21 except for one patient who had a high expression of 
both markers. No trends or associations were detected between miR-29a and CD147 or miR-21 
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Figure 12: Relative expression levels of miR-21 and miR-29a and histological protein expression of 
CD147. 
A) Tumour relative expression of miR-21 in CD147 positive verse negative tumours (p=0.0481, 
unpaired t-test). B) No associations were detected between miR-29a and CD147. C) No correlation 






3.5 IMMUNOHISTOCHEMICAL EVALUATION OF CD147 STAINING IN THE STAGE II 
LYMPH NODES  
3.5.1 IMMUNOHISTOCHEMICAL EVALUATION OF CD147 STAINING IN STAGE II COLON 
CANCER LYMPH NODES  
As mentioned previously, the optimised IHC protocol was applied to stage II and III patient samples, 
including the TDLNs, available as 3mm cores within recipient TMA blocks. Lymph nodes from a non-
cancer patient (diverticulosis) were also stained for CD147.  
A substantial amount of staining was observed in all lymph node samples, including the non-cancer 
lymph nodes (figure 13D). This staining was predominantly present in the B cell GCs of the lymph 
nodes. Initially this staining pattern was not expected because according to the human protein atlas 
(90), CD147 is not expressed in unstimulated or stimulated lymph nodes (characterised by the 
formation of follicles and GCs) of the gastrointestinal tract (figure 13A, B). However, upon further 
investigation it is more likely that CD147 is expressed in activated T cell and B cells according to the 
Human CD Marker Chart (91) and a previous report in the normal adjacent lymph nodes of patients 
with B cell lymphomas (92).  
For this reason, the tumour-associated expression of CD147 could not be explored. Instead, the 
project shifted focus towards exploring the morphological patterns in the stage II, III and non-cancer 
lymph nodes. Despite, this change of direction, the ultimate aim of discovering biomarkers was still 
persistent.  
3.6 HISTOLOGICAL MORPHOLOGY OF STAGE II COLON CANCER LYMPH NODES  
A total of 146 lymph node cores from stage II colon cancer patients were examinable (where more 
than 50% of the 3mm cores had tissue present) with an average of 10 lymph nodes per patient. In 
most cases (n=8) patients had more than 10 examinable lymph nodes, in 4 cases there were 5-9 
examinable lymph nodes and in 3 cases there were 3 examinable lymph nodes. There was no 
evidence of metastasis in the stage II TDLNs. For the stage III patient (positive control), 20 TDLNs 
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examinable. However, metastatic deposits were present in 80% (n=16/20) of them. For the non-
cancer patient (negative control), all 3 surgically resected lymph nodes were examinable.  
3.6.1 QUALITATIVE ANALYSIS OF LYMPH NODE B CELL COMPARTMENTS   
All stage II TDLNs (n=126) except 1, formed B cell follicles and GCs and were therefore considered 
stimulated lymph nodes (figure 13D). Only one TDLN of the stage III patient formed these B cell 
compartments (figure 13H), the rest were infiltrated with metastatic deposits or unresponsive. All 3 
of the non-cancer lymph nodes were stimulated.  
Comparison of non-cancer stimulated lymph nodes compared to stage II cancer-specific stimulated 
lymph nodes revealed differences in the number, relative size and roundness of follicles and GCs  
(figure 13D, E, F). Of the 3 non-cancer stimulated lymph nodes, there was an average of 3 follicles 
and GCs per lymph node (figure 13C) while an average of approximately 11 follicles and 8 GCs were 
observed for the stage II TDLNs (table 6). While no striking differences were observed between the 
non-cancer and stage II lymph nodes in terms of the average follicle and GC size (table 6), some 
stage II lymph nodes formed large, irregular shaped follicles (figure 13E, F). This pattern was not 
seen in the non-cancer lymph nodes that were all consistent in shape and size (figure 13C).  
We did not compare these findings to the stage III TDLNs because only one formed follicles and GCs. 
However, no primary follicles can be seen in the non-cancer lymph nodes, while primary follicles 
without GCs are evident in both stage III and II lymph nodes (figure 13H). 
 
Table 6: Average follicle and GC density and size in non-cancer lymph nodes and stage II TDLNs 
 Non-cancer lymph nodes Stage II TDLNs 
GC density 3 7.899946 
F density 3 11.402 
F size (mm) 0.141222 0.1431 































Figure 13: B cell follicles and GCs in lymph nodes from different patient origins stained for CD147. 
A) Unstimulated lymph node characterised by the lack of follicles and GCs. No CD147 staining 
present. Data from the Human Protein Atlas (90) however, patient of unknown origin B) Stimulated 
lymph node from the same patient characterised by the formation of a single follicle and GC. 
However, there is no CD147 staining in the GC (I) while CD147 staining was present in all GC in this 
study. C) Non-cancer lymph nodes. D) Typical stage II lymph node. E) Stage II lymph node with a 
large, irregular GC (II). F) Stage II lymph node with a fused/non-circular GC (II). G) Typical stage III 















3.6.2 ASSOCIATIONS BETWEEN PATHOLOGICAL RISK FACTORS AND 
HISTOMORPHOLOGICAL DIFFERENCES IN LYMPH NODES  
To address the hypothesis that histomorphological changes in the draining mesenteric lymph nodes 
of stage II colon cancer patients is associated with pathological risk factors the number and size of 
follicles and GC were correlated with T stage, dMMR status, lymphatic invasion and tumour grade 
(figure 14, 15, 16, 17). 
Patients with T3 tumours tended to have a lower GC density (7.168 ± 1.805) compared to patients 
with T4a/b tumours (9.546 ± 3.375) (figure 14B). The same trend was seen for GC size where 
patients with T3 tumours had a lower GC size (0.03422 ± 0.004963) compared to patients with T4a/b 
tumours (0.09664 ± 0.02714) (p=0.0516) (figure 14C). Similarly, patients with T3 tumours tended to 
have a smaller follicle size (0.1153 ± 0.009043) compared to patients with T4a/b tumours (0.2057 ± 
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Figure 14: Lymph node morphology and T stage  
A) GC density in patients with T3 tumours versus T4a/b tumours (p=0.0993 Mann-Whitney t-test. C) 
GC size in patients with T3 tumours versus T4a/b tumours (p=0.0516, Welch’s t-test. E) Follicle size in 
patients with T3 tumours versus T4a/b tumours (p=0.0851, Welch’s t-test). B, D) No other trends or 
associations found.  
Patients with evidence of dMMR had a higher number of follicles per lymph node (13.05 ± 0.946) 
compared to patients without dMMR (9.417 ± 1.42) (figure 15b). This association was significant 
(p=0.0364). Similarly, patients with evidence of dMMR had a higher number of primary follicles per 
lymph node (5.385 ± 1.278) compared to patients without MSI (1.704 ± 0.3971) (figure 15C). This 























































































Figure 15:Lymph node morphology and dMMR status. 
B) Follicle density in patients with dMMR verse those without (p=0.0364, unpaired t-test). C) Primary 
follicle density in patients with dMMR verse those without (p=0.0424, Welch’s t-test). A, D, E) No 
other trends or associations found. * = p value < 0.05. 
           
Patients with evidence of lymphatic invasion tended to have a smaller follicle size (0.109 ± 
0.0009069) compared to patients without lymphatic invasion (0.1644 ± 0.02928) (figure 16E). This 
association did not reach statistical significance, but a trend was observed (p=0.0212). The same 









± 0.004187) compared to patients without lymphatic invasion (0.06503 ± 0.01805) (p=0.0717) (figure 
16D). Patients with lymphatic invasion also had a lower GC density (6.327 ± 0.7963) compared to 
patients without lymphatic invasion (8.883 ± 0.8775), this association was statistically significant 
(p=0.0360) (figure 16B).   
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Figure 16:Lymph node morphology and lymphatic invasion. 
B) GC density in patients with lymphatic invasion versus those without (p=0.0360, unpaired t-test). D) 
GC size in patients with lymphatic invasion versus those without (p=0.0717, Welch’s t-test). E) Follicle 
size in patients with lymphatic invasion versus those without (p=0.0212, Welch’s t-test). A, C) No 














Patients with high grade tumours had a lower primary follicle density (1.44 ± 0.4103) compared to 
patients with low grade tumours (4.416 ± 1.012) (figure 17C). This was statistically significant 
(p=0.0429). No other associations or trends were detected between tumour grade and GC density, 
follicle density, GC size and follicle size (figure 17A, B, D, E).  











































































Figure 17:Lymph node morphology and pathological grade. 
High grade= moderately-poorly differentiated, low grade= well differentiated. C) Primary follicle 
density in patients with high grade versus low grade tumours (p=0.0429, unpaired t-test). A, B,D, E) 















3.7 MIR-21 EXPRESSION LEVELS IN THE STAGE II TUMOUR-DRAINING LYMPH 
NODES  
To detect and characterise the expression levels of miR-21 in the lymph nodes of stage II colon 
cancer patients, RT-qPCR was performed in FFPE TDLNs of stage II patients and the lymph nodes of 
the non-cancer patient. The geometric mean of miR-345 and miR-16 was used to normalise the 
expression levels of miR-21. miR-29a was not measured due to time constraints. Further, RT-qPCR 
was not applied to all lymph nodes of the entire stage II cohort. Instead, 23 randomly chosen lymph 
nodes from all patients were involved in this analysis (figure 18). 
A greater variation in miR-21 levels in the TDLNs of stage II patients was observed compared to the 
lymph nodes of the non-cancer patient (negative control) (figure 18). In particular, a 3-8-fold 
increase in expression levels was detected in 8 stage II TDLNs compared to negative controls (figure 
18).  


























Figure 18: miR-21 relative expression levels in the TDLNs of stage II colon cancer patients and the 
















CHAPTER 4: DISCUSSION 
4.1 KEY FINDINGS 
The overall aim of the current study was the characterise the expression of CD147, miR-21 and miR-
29a in the tumours and/or TDLNs in a small pilot cohort of stage II colon cancer patients. The key 
findings include; 1) CD147 and miR-21 are overexpressed in 60% and 50% of these patients 
respectively; 2) CD147 cannot be used as a tumour-associated biomarker in the TDLNs; 3) miR-21 
expression levels were dysregulated in TDLNs compared to non-cancer lymph nodes; 4) In a 
histological manner, a large variation in the number, size and shape of B cell compartments in the 
TDLNs was found between stage II colon cancer patients;  Here we discuss, in depth, the findings of 
the current study and how these findings are significant to the current field of research. We also 
discuss the limitations and strengths of the methodology used as well as steps to take in the future. 
4.2 SAMPLE SELECTION FROM THE SCRG BIOBANK 
4.2.1 PATIENT SELECTION AND COHORT SIZE   
Colorectal cancer patient recruitment has been ongoing at Wellington Hospital from November 2016 
with a current recruitment rate of 1-2 patients per week. At the beginning of the study period 
(March 2018) a maximum of 13 stage II colon cancer patients, that fitted the inclusion criteria, had 
been recruited into the biobank.   
One requirement that significantly reduced the number of available patients was the exclusion of 
rectal patients due to the likelihood of them receiving neoadjuvant therapy which would introduce 
confounding factors. For example, neoadjuvant (chemo)radiation therapy is known to introduce 
morphological changes both in the primary tumour and the draining lymph nodes. Fibrous or 
fibroinflammatory tissue is of note, as this can obscure carcinoma cells within a tumour and 
morphological compartments within lymph nodes (85). Further, the design of this cohort was to 
simply characterise and explore the potential prognostic significance of biomarkers in patients who 
have not received any additional therapy other than surgical resection of the primary tumour.  
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While the cohort size in this pilot study was small it was sufficient enough to establish and optimise 
techniques in the lab for the detection of CD147, miR-21 and miR-29a for future, larger cohorts. 
Further, the expression of these markers could be characterised and hypotheses formed as to their 
prognostic significance in stage II colon cancer patients.  
4.2.2 ETHICAL CONSIDERATIONS 
One component of the ethical considerations was the need to ensure adequate representation of 
Māori within the study. Statistically Māori represent approximately 6% of all CRC cases in New 
Zealand (2). Fortunately, one of the thirteen patients was Māori, which meant we could more 
accurately represent the true population of CRC in New Zealand. A challenging aspect of this 
consideration in an emerging biobank though, is we can only deal with the set of patients we are 
given. This means we may over represent or under represent Māori. This is something that should 
be considered in the research design for future, prospective studies. 
4.2.3 POSITIVE AND NEGATIVE CONTROLS 
The tumour cell positive lymph nodes from a stage III patient and the non-cancer lymph nodes from 
a diverticulosis patient were particularly useful for qualitative comparison to the stage II lymph 
nodes. Comparisons were hypothesis-generating around the prognostic potential of 
histomorphological changes in the stage II lymph nodes.  
Ideally, more negative controls would have been selected however, only rarely would non-cancer 
patients, with surgically resected lymph nodes be recruitment into the biobank. This is due to the 
framework of our study and ethical approval which requires that patients either have confirmed 
diagnosis of cancer or a high suspicion of cancer at the time of surgery. Recruitment of the non-
cancer patient was only possible as there was initially a high suspicion of cancer in the clinic. 
However, it must be noted that the role of the positive and negative control was never to perform 
formal statistical analysis. Instead the purpose of these controls was more for qualitative 
comparisons and to explore differences.  
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4.2.2 SAMPLE COLLECTION AND SAMPLE TYPE 
While formalin-fixed lymph nodes were retrievable for all stage II patients, fresh paired tumour and 
normal mucosa samples were only banked for 10 of these patients. Samples from the remaining 
patients in the cohort could not be taken without compromising pathological assessment due to the 
specimens being too small, which is sometimes the case for early-stage colon cancers (5). Therefore, 
samples were not available for biobanking, a limitation of the study. 
Regarding the lymph nodes collected, the use of formalin-fixed tissue, as opposed to fresh, was 
more appropriate for two reasons. Firstly, it is difficult to bank surgically resected lymph nodes as 
this would comprise pathological staging of cancers therefore, the tissues were retrieved after their 
fixation and subsequent assessment. Secondly, for immunostaining and morphology, FFPE samples 
produce better quality of histomorphology compared to fresh tissues (93). FFPE samples also allow 
for efficient long-term storage for prospective studies (93). 
 
4.3 ESTABLISHMENT AND OPTIMISATION OF METHODOLOGIES  
Part of our first objective in the current study was to establish and optimise the molecular 
techniques for the detection of CD147, miR-21 and miR-29a in the tumours and normal mucosa 
tissues of stage II colon cancer patients. We successfully optimised primary antibody conditions to 
detect a strong CD147 signal that could distinguish between tumour and normal mucosa tissues 
without introducing non-specific staining. Using RT-qPCR, we were also able to detect miR-21 and 
miR-29a in tumour and normal mucosa samples frozen in RNAlater. Further, we were able to 
validate miR-345 and miR-16 as endogenous controls for these samples.   
4.3.2 LIMITATIONS OF RNA ANALYSIS IN FFPE LYMPH NODES 
Detecting tumour-associated CD147 and miR-21 in the TDLNs of these stage II patients was also an 
important part of our first objective. While CD147 was detectable in the TDLNs using the same IHC 
protocol for the tumour tissues, we discovered this signal was not tumour-specific or at least any 
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tumour-specific signal was not distinguishable. Non-cancer specific CD147 staining in TDLNs is 
discussed in more detail in chapter 4.8. 
Concerning the detection of miR-21 in the TDLN FFPE tissues using RT-qPCR, we were not able to 
validate endogenous miRNA controls for the normalisation of miR-21. A large variation in Ct values 
was observed in the lymph nodes for both mi-345 and miR-16 endogenous controls whereas, Ct 
values were within 2 units for the fresh tumour and normal mucosa tissue. Despite this, no statistical 
differences were observed between the non-cancer and stage II lymph nodes in terms of mean Ct 
values and standard deviations. This suggests the observed variation may be due to differences in 
RNA integrity in FFPE tissues versus fresh tissue. All lymph nodes were retrieved as FFPE samples 
from the hospital laboratory therefore, variables such as time between resection and effective 
fixation as well as fixation time may have affected the RNA integrity in these samples (94). Despite 
this, we cannot attribute sample processing to the observed variation in Ct values due to a low 
number of non-cancer lymph nodes for comparison.  
4.3 TUMOUR CD147 EXPRESSION AS A PROGNOSTIC AND PREDICTIVE 
BIOMARKER IN STAGE II COLON CANCER 
4.3.1 CURRENT AND PREVIOUS FINDINGS  
CD147/EMMPRIN is the most overexpressed, membrane-bound protein on disseminated cancer cells 
(61) and is overexpressed in CRC tumours (59, 62, 63, 64) representing a potential biomarker. The 
second objective of this study was to characterise the expression levels of CD147 in the tumours of 
stage II colon cancer patients to begin to understand its prognostic potential in this population.  
The current finding is that CD147 is overexpressed in 60% of stage II tumours compared to normal 
mucosa tissue with the location predominantly membranous. This is consistent with many 
publications, whereby CD147 in tumours, in populations consisting of all TNM stages, is 
overexpressed compared to normal adjacent mucosa (59, 62, 63, 64). While majority of these 
studies do not report CD147 expression in stage II patients separately, the two studies that have, 
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report CD147 is overexpressed in approximately 50-76% of stage II patients (63, 64). This is in line 
with the current finding.  
Although the number of patients in the present was too small to compare CD147 status and 
pathological factors, previous studies have detected significant associations in support of the 
prognostic significance of CD147 in CRC. Associations between extramural vascular or lymphatic 
invasion, high grade tumours, lymph node positivity and distant metastasis in populations of all TNM 
stages have been detected (62, 63). Further, CD147 has been shown to be an independent 
prognostic factor for DFS (62, 63). While other studies have not been able to replicate this (59, 64) a 
meta-analysis revealed a significant association between CD147 expression and OS (58), although 
this was not independent of other prognostic factors. Taken together, this at least suggests CD147 is 
a potential risk factor in CRC patients that needs more investigation.  
4.3.2 PREVIOUS FINDINGS OF CD147 IN STAGE II CRC 
Existing evidence from previous studies that specifically assess the prognostic significance of CD147 
in stage II CRC patients is more contradictory. While Stenzinger and colleagues (2011) found a 
significant difference between stage II CRC patients with high and low CD147 expression in terms of 
cumulative survival, Boye and colleagues (2012) failed to find any prognostic impact in stage II 
patients (63, 64). No apparent differences in sample size, follow-up time or methodologies were 
observed between these two studies however, rates of chemotherapy were not reported. Therefore, 
the prognostic significance of this marker in stage II colon cancer patients is unclear. However, the 
consistent findings that CD147 overexpression is associated with lymph node positivity, distant 
metastasis, metastasis-free survival and OS in populations consisting of all TNM stages suggest 
CD147 could still be useful in earlier CRC patients (62, 63).  
4.3.3 FUNCTIONAL RELEVANCE OF CD147 TO STAGE II COLON CANCER 
Evidence from preclinical studies suggest CD147 may be implicated in the recurrence of cancer 
supporting the potential role of CD147 as a prognostic biomarker in stage II colon cancer patients. 
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CD147 is directly involved in metastasis through its regulatory activity of matrix metalloproteinases 
(MMPs) (57). CD147 expression on the cancer cell surface stimulates the secretion of MMPs from 
cancer cells themselves and the surrounding stroma (57). Subsequent MMP-mediated degradation 
of the ECM alters its biochemical composition, promoting anti-apoptosis and removes the physical 
barrier promoting tumour growth, angiogenesis and importantly, invasion and metastasis. 
Considering CD147 is likely an important initiator of the metastatic cascade in a clinical context, 
areas of the tumour with particularly high CD147 expression could allow the development of 
micrometastasis (57). In stage II colon cancer patients with high CD147 expression, this would 
warrant the administration of adjuvant chemotherapy.   
While the role of adjuvant chemotherapy is to eradicate micrometastatic disease after the removal 
of the primary tumour in stage II patients, (34) preclinical evidence also suggests CD147 may be 
involved in chemotherapy resistance. Xu et al (2014) and Peng et al (2015) revealed high CD147 
expression decreased the sensitivity of CRC cells to 5-FU and Oxaliplatin respectively, which are two 
major chemotherapeutic regimens in stage II colon cancer (95, 96). While the exact mechanism for 
CD147 mediated drug resistance is unclear, the influence of CD147 on receptor tyrosine kinase’s, 
ABC transporters and Monocarboxylate transporters is likely to blame (97). As of yet, no clinical 
associations have been made in CRC patients although, associations between CD147 and 
chemoresistance in bladder, ovarian and lung cancer have been detected (98, 99, 100). Taken 
together, CD147 could be a potential contributor to recurrence after surgery in stage II colon cancer 
patients, despite receiving adjuvant chemotherapy. 
4.3.4 STRENGTHS AND LIMITATIONS OF THE CURRENT STUDY  
One aspect of the current study that potentially limits the comparability of this study to previous 
studies was the inability to develop an immunoreactivity score (IRS). The first objective of this study 
was to establish experiment techniques for the detection of CD147 in tumour tissue. However, one 
issue we came across was the poor representation of dense tumour tissue as 3mm cores within 
76 
 
TMAs. Within these cores, only small areas of dense tumour tissue was present. While the intensity 
of staining was consistent across the sample area the extension or frequency of positively stained 
cells could not be accurately determined. Therefore, a semi-quantitative IRS, which combines both 
the intensity and extension of staining, could not be developed.  
The extension of staining is an important parameter particularly concerning the biological 
heterogeneity of tumours (101). Further, considering the metastatic potential of CD147-expressing 
cancer cells (58), high overexpression in one area of the tumour may be more of a risk factor than 
moderate overexpression across the entire sample. For this reason, an IRS is the standard 
methodological approach for semi-quantification of CD147 (59, 62, 63, 64). 
Despite this limitation, one potential advantage of our approach was the use of the intensity ratio 
between matched tumour and normal mucosa as opposed to a grouped comparison of all tumours 
compared to normal mucosa tissues. The standard approach for determining the overexpression 
CD147 in tumours is by calculating the IRS for each tumour and normal mucosa sample. A cut-off IRS 
value is then determined to group samples into positive and negative staining groups (59, 62, 63, 
64). However, this does not consider normal mucosa with moderate amounts of staining relative to 
adjacent tumour tissue. Therefore, we believe the ratio of intensity between non-malignant and 
malignant tissues serves as a more informative clinical marker to determine CD147 positive tumours. 
This also allows for a within-subject comparison which is more rigorous than a group analysis. This 
statement is agreement with a previous study that also observed considerable staining in the normal 
tissues of CRC patients (102).  
4.3.5 CONCLUSION 
To summarise, this study found that CD147 is overexpressed in 60% of stage II colon tumours which 
is consistent with previous studies. A caveat of this work is the positivity rate is purely from 
qualitative assessment of staining intensity. In terms of the potential for CD147 as a biomarker in 
stage II colon cancer patients, associations between CD147 and pathological factors in previous 
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studies support this role. Further, the functional role of CD147 in metastasis, recurrence and 
chemoresistance in preclinical studies suggests this marker may be relevant to stage II colon cancer 
patients. Overexpression of CD147 may highlight patients at a higher risk of developing recurrence 
and those less likely to respond to adjuvant chemotherapy. While the current and previous findings 
are promising, further research is required to determine the clinical relevance of this biomarker in 
these patients. 
4.4 TUMOUR MIR-21 EXPRESSION AS A PROGNOSTIC AND PREDICTIVE 
BIOMARKER IN STAGE II COLON CANCER  
4.4.1 CURRENT AND PREVIOUS FINDINGS 
miR-21 is the most consistently cited oncomiRNA (50). miR-21 is upregulated in a number of diverse 
human cancer types including CRC (103) and is a potential biomarker for stage II colon cancer. To 
achieve the second objective, which was to characterise the expression of miR-21 in the tumours of 
stage II colon cancer patients, we performed RT-qPCR. We found a trend towards overexpression in 
the tumours compared to the normal mucosa. A positivity rate (number of patients with a relative 
expression >1) of 50% was observed. Positive relative expression ranged between 1.61 to 3.5. 
Strikingly, 2 of these patients had more than a 2-fold increase in relative expression. Moreover, the 
considerable variation in the relative expression levels of the tumours compared to the normal 
mucosa tissues suggests that it’s part of the molecular heterogeneity we see in the tumours of these 
patients and could be reflective of a molecular subtype (104). 
Interestingly, three distinct populations can be seen, those with high overexpression of miR-21 (>3-
fold), moderate overexpression (>1.5-fold) and those with expression equivalent to adjacent normal 
mucosa tissue. In a future, larger cohort if this trend held true and a multimodal distribution was 




To explore the potential prognostic significance of this overexpression, we compared miR-21 levels 
with pathological risk factors. Unexpectedly, a trend towards statistical significance was observed 
between T stage and miR-21 relative expression. Patients with a high T stage (T4a/b) tended to have 
a lower tumour relative expression of miR-21 compared to patients with T3 tumours. However, it 
must be noted that only 3 patients had T4a/b tumours. Further, no other trends or associations were 
detected between miR-21 levels and lymphatic invasion or tumour grade. Overall, the true 
prognostic significance of miR-21 in stage II colon cancer patients cannot be derived from this data 
largely due to a small sample size. 
In comparison to previous findings a significant overexpression of miR-21 in CRC tumours has 
consistently been described in several small clinical studies across different populations as well as 
some larger scale ones (42, 46, 52, 105,).  These studies have additionally found associations with 
lymph node positivity, development of distant metastasis or advanced TNM stage and poorly 
differentiated tumours, strengthening the potential for miR-21 as a biomarker in this cancer type. 
Subsequently, several studies have found associations with OS and DFS (41, 46, 52) in populations 
consisting of all TNM stages. In general, a stepwise increase has been observed from adenomas to 
advanced TNM stage suggesting patients with high miR-21 levels at an early stage are more likely to 
progress to later stages of the disease (46). In other words, elevated miR-21 is a potential risk factor 
for stage II colon cancer patients.  
4.4.2 PREVIOUS FINDINGS OF MIR-21 IN STAGE II CRC  
Only a few studies have specifically analysed miR-21 expression levels in stage II CRC patients. 
However, all of these studies have revealed a significant overexpression of miR-21 in tumours 
compared to normal mucosa tissues, consistent with the current findings (46, 106, 107, 108). Of 
these, only two studies have reported the positivity rate of miR-21 in stage II CRC tumours. Shibuya 
et al (2010) reported 15.8% as the positivity rate in Dukes stage A, B (TNM stage I and II). While this 
seems relatively low, the stepwise increase in miR-21 levels suggests a slightly higher rate would be 
79 
 
expected for Dukes stage B alone, which is equivalent to TNM stage II. Kang et al (2015) reported 
28.3% of stage IIA/B patients had high miR-21 levels which is more consistent with our findings. Of 
note however, is the exclusion of T4b tumours. Others have reported an association between 
elevated miR-21 levels and advanced T stage (42, 46, 52), suggesting the positivity rate is likely more 
than 28.3%. Further, a lack of transparency regarding cut-off values to determine positivity rates 
reduces the comparability of these studies to the current one. 
Associations between miR-21 levels and pathological factors have further been detected in stage II 
CRC patients. A study in 764 stage II colon cancer patients found high miR-21 levels were associated 
with decreasing recurrence-free cancer-specific survival independent of clinicopathological risk-
factors (108). In agreement with this was a study by Nielson et al (2011) and Kang et al (2015) that 
found high miR-21 levels in stage II colon cancer patients correlated with DFS. Currently, Nielson et 
al are the only authors to find a significant association with OS while others have failed to validate 
this likely due to insufficient power. Taken together, previous findings support the notion that 
elevated miR-21 is a potential risk factor for the population of interest.  
4.4.3 FUNCTIONAL RELEVANCE OF MIR-21 TO STAGE II COLON CANCER 
Preclinical studies implicate miR-21 in aspects of initiation, progression and chemoresistance in 
cancer. These findings suggest miR-21 is likely implicated in recurrence of disease which is of 
particular relevance to stage II colon cancer patients and supports clinical findings that elevated miR-
21 is a risk factor for these patients. 
miR-21 is best characterised as a proinflammatory marker in cancer (38). As such it has been 
implicated in an NF-kB inflammatory positive feedback loop that initiates an epigenetic switch from 
non-transformed cells to stable cancer cells (47). A core target of miR-21 in this loop is the tumour 
suppressor PTEN and an inverse correlation has also been detected in CRC clinical samples between 
these two molecules (48). The consistency of this positive feedback loop (and other inflammatory 
mechanisms) may also lead to a progressive increase in COX-2, which indirectly increases miR-21 to 
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progressively decrease its direct target, PDCD4, promoting the tumour to more malignant states 
(109). Again, an inverse relationship between miR-21, COX-2 and PDCD4 has been detected in 
human CRC tissues (109). Strikingly, aspirin use is associated with reduced recurrence and distant 
metastasis in sporadic CRC (110). The main action of aspirin is to target COX-2 (109). Taken together, 
this implicates miR-21 as being functionally relevant in early colon cancer and promoting the 
progression and recurrence of cancer in these patients. 
Considering the number of gene targets miR-21 has (both known and unknown), the ability for miR-
21 to promote chemoresistance is unsurprising (50). As such, evidence from cell culture and 
xenografts studies suggest miR-21 may also be involved in 5-FU resistance in CRC (49). Valeri and 
colleagues (2010) demonstrated the ability for miR-21 to downregulate MSH2 and MSH6, which 
make up the core MMR recognition protein complex. CRC cells and xenografts overexpressing miR-
21 reduced 5-FU-induced G2/M damage arrest and subsequent apoptosis. A comparable response 
was also seen in dMMR cell lines (49). Considering MSI is a predictive biomarker to adjuvant 
chemotherapy (33), miR-21 could also be used to predict those patients with MSS tumours that 
won’t respond to chemotherapeutic regimens such as 5-FU.  
4.4.4 CONCLUSION 
Overall, our findings support those of previous clinical studies that miR-21 is upregulated in stage II 
colon cancer patients. A strong trend towards overexpression was detected in this population and 
while the sample size was small, due to the high level of precision RT-qPCR provides us with we 
believe a significant association would be detected in a larger cohort. Our data also highlight distinct 
subsets of populations that could be used to stratify patients in future, larger cohorts. Evidence from 
preclinical and clinical studies also support the notion that miR-21 is a potential risk factor for stage 
II patients however, more research is required for conclusive evidence.  
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4.5 TUMOUR MIR-29A EXPRESSION AS A PROGNOSTIC BIOMARKER IN STAGE II 
COLON CANCER  
4.5.1 CURRENT AND PREVIOUS FINDINGS 
miR-29a is known to be downregulated in most cancer types and has been associated with tumour-
suppressing roles (114). Conversely, it is thought to be overexpressed in CRC, (44, 45, 53) making 
miR-29a a particularly attractive biomarker because of its potential specificity to CRC. Like miR-21, 
miR-29a was characterised in tumours of the same patient cohort using RT-qPCR to achieve our 
second objective. 
In the current study we found no significant association between tumour and normal mucosa 
relative expression levels. Although our sample size was small, only 1 patient exhibited a significant 
overexpression of this marker (>1.5-fold increase). Instead a small trend towards downregulation 
was observed in the remaining 9 patients. Further, the remaining 9 patient’s tumour levels clustered 
together, analogous to the normal mucosa levels. This suggests that in early-stage colon cancer, 
unlike miR-21, miR-29a is not profoundly dysregulated in most patients and may not be a strong risk 
factor for this population. Our results show there is evidence of heterogeneity of expression of this 
miRNA which in a larger cohort of patients could potentially represent a subset of overexpressing 
patients. 
Conversely, a previous report of miR-29a levels in patients of all TNM stages revealed a significant 
upregulation compared to normal mucosa (44), in agreement with another study that found miR29a 
to be significantly higher in the tumour tissue of metastatic CRC patients compared to non-
metastatic CRC patients (111). Despite this, no other studies have found associations with T stage, 
TNM stage or other clinicopathological risk factors therefore, further research is warranted to 
confirm the association between elevated miR-29a levels and poor patient outcomes in CRC. 
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4.5.2 PREVIOUS FINDINGS OF MIR-29A IN STAGE II CRC 
The only previous study to report miR-29a expression levels in stage II patients was by Weissmann-
brenner et al (2012) where patients were stratified into two groups; those with a poor prognosis and 
those with a good prognosis based on the present or absence of recurrence (112). Patients with a 
good prognosis had a small but significant increase in miR-29a levels in the tumour compared to 
patients with a poor prognosis. However, miR-29a levels were not normalised to adjacent normal 
mucosa, a limitation of the study. Therefore, it is not known whether “high” levels of miR-29a in this 
study are actually overexpressed compared to normal mucosa. Perhaps downregulation of miR-29 is 
associated with a higher risk of recurrence as opposed to an upregulation being associated with a 
lower risk of recurrence. 
If a downregulation is associated with a poor prognosis, the trend towards downregulation in our 
study was particularly small and we do not believe this would have a significant impact on patient 
outcomes in a larger, future cohort of stage II colon cancer patients. Based on previous findings, we 
believe the upregulation of this marker to be more compelling. Further, a study in stage III CRC 
patients found miR-29a to be significantly upregulated in tumour compared to normal mucosa (45). 
This is interesting considering a small subset of stage II colon cancer patients are known to have 
survival rates approximating stage III (13). 
It cannot be concluded from this study whether the patient with elevated miR-29a is simply an 
outlier or is a true representation of this population due to the sample size. However, clustering of 
the remaining patients with a trend towards downregulation of miR-29a accentuates the patient 
with elevated miR-29a. Analogous to miR-21, in a future, larger cohort if a bimodal distribution was 




4.5.3 FUNCTIONALITY OF MIR-29A 
What may explain discrepancies in the literature is for the ability for miR-29a to both promote and 
suppress tumourigenesis. The dual mechanisms of miR-29a is a theme found in many miRNAs which 
is unsurprising given the large number of genes influenced by a single miRNA species (113, 39). 
Specifically, in CRC cell lines and mouse models, miR-29a has been shown to target KLF4, promoting 
cell invasion by inhibition of E-cadherin expression (38). An inverse correlation was observed 
between miR-29a and KLF4 in clinical CRC samples and both a high level of miR-29a and low level of 
KLF4 was associated with distant metastasis and poor prognosis (44). Conversely, in breast cancers, 
an overexpression of miR-29a was significantly associated with slower growth of breast cancer cells 
(114). Evidence from breast cancer cell lines suggest this association may be through down-
regulation of B-Myb, a regulator of cell proliferation and survival (114). Similarly, in gastric cancer, 
miR-29a inhibited cell proliferation and wound healing by downregulation of several cyclin-
dependent kinases (115).  
The role of miR-29a in CRC and whether it has a dual role in CRC has not been sufficiently described. 
Therefore, it cannot be concluded whether the up- and/or down-regulation of miR-29a in stage II 
colon cancer patients is directly associated with tumourigenesis. It has also been suggested for 
microRNAs with a dual role in cancers, that it is important to determine whether their net effect is 
oncogenic or tumour suppressive and even then, their use as biomarkers or drug targets should be 
cautioned (39).  
4.5.4 CONCLUSION 
In our small cohort of patients, it appears that miR-29a is not considerably dysregulated in this 
population. However, based on a previous report (44), the elevated levels of miR-29a in a single 
patient may be representative of a small subset of stage II colon cancer patients. Combined with a 
small amount of preclinical evidence, this overexpression may be functionally relevant in this patient 
group although, the potential duplicity of this marker needs to be determined. Taken together, 
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further research in a larger cohort is required to confirm a potential bimodal distribution in stage II 
colon cancer patients.  
4.6 STRENGTHS AND LIMITATIONS OF RT-QPCR FOR THE DETECTION OF MIRNAS  
A notable difference in methodologies of the current study compared to many previous studies is 
the use of in situ hybridisation (ISH) for the evaluation of miR-21 levels (46, 106, 107, 108). This limits 
the comparability of the present study to previous ones and highlights the advantages and 
disadvantages of using RT-qPCR. While RT-qPCR is a strong quantitative tool with a high level of 
precision and reproducibility (86), one major setback is the masking of non-cancerous tissue, such as 
normal mucosa, in the samples (108). Therefore, in situ hybridisation (ISH) using locked nucleic acid 
(LNA) modified by DNA probes has been employed by some researchers to semi-quantitatively 
measure the miR-21 signal in FFPE samples (107, 108). Of note, ISH has not been employed for the 
detection of miR-29a in CRC tissue likely due to the lack of publications in this area however, it has 
been employed in other cancer types (116). However, we believe it was appropriate to use RT-qPCR 
in the current study because samples were taken from central tumour and examination of H&E 
reference slides revealed no significant amount of non-tumour tissue. 
One potential limitation however, is the inability to detect the localisation of the miRNAs.  ISH allows 
the cellular and subcellular localisation (108) of miRNAs which could be more informative as 
opposed to an ‘average’ measure of all cell types within a tissue sample quantified by RT-qPCR.  
In a clinical context ISH and RT-qPCR can both be performed on FFPE tissues to measure microRNAs 
and modified to be high-throughput, suggesting the cost and time-efficiency of these techniques 
would be similar in a clinical laboratory. Further, while ISH may be less reproducible, as it is 
susceptible to a certain level of observer bias, the ability to localise the mi-21 and miR-29a signal 
may be a more powerful prognostic measure compared to RT-qPCR. Ultimately, whether RT-qPCR or 
ISH is more clinically feasible and has more prognostic potential cannot be determined until both are 




4.7 OVERALL SIGNIFICANCE OF TUMOUR MARKERS 
4.7.1 SIGNIFICANCE OF CD147, MIR-21, MIR-29A AS PROGNOSTIC BIOMARKER IN 
STAGE II COLON CANCER PATIENTS 
CD147 and miR-21 are relevant prognostic biomarkers for stage II colon cancer patients for several 
reasons. Firstly, data generated from the current study show both of these markers are considerably 
dysregulated in this population, with at least 50% of patients exhibiting an elevated expression of 
either marker. This implies CD147 and miR-21 may have functional relevance in this population. 
Conversely, miR-29a was only significantly upregulated in 1 stage II patient and overall, no 
substantial dysregulation was observed. Secondly, the stepwise increase in expression levels of these 
markers from early to late stage CRC, reported in the literature, suggests an elevated expression in 
stage II patients is a potential risk factor (46). Lastly, combined with accumulating evidence for 
independent associations between CD147, miR-21 and lymph node positivity, distant metastasis and 
DFS described above, the data presented here support the notion that the elevation of these 
markers are directly involved in disease advancement in stage II colon cancer patients. 
Data from preclinical studies exploring the potential functionality of these markers further support 
their direct involvement in disease progression in stage II colon cancer patients. As suggested, 
functional biomarkers, such as MSI status, which has a known causal role in the behaviour of the 
tumour (36), allow clinicians to strategically target specific patient groups. As such, the direct role of 
CD147 and miR-21 in promotion of inflammation, invasion and metastasis implicates them in disease 
recurrence making them more valuable (38, 57). On the other hand, miR-29a appears to be both 
oncogenic and tumour suppressive (113) and be both upregulated and downregulated in CRC. This 




The relevance of CD147 and miR-21 extends to their ability to detect specific subsets of stage II 
patients. For example, the combination of CD147 and miR-21 revealed a single patient with elevated 
expression of both markers. Evaluating the prognosis of patients with these characteristics, 
compared to patients with overexpression of only one marker, would be of interest. Further, the 
functional roles of these markers in chemoresistance (49, 95, 96) suggest they could be predictive of 
outcomes to treatment for some patients. It could be hypothesised that miR-21 may detect patients 
with MSS tumours that will not respond to chemotherapy. Ultimately, these markers could detect 
stage II patients at a higher-risk of recurrence who will also receive no benefit from adjuvant 
chemotherapy, reducing the mortality and morbidity associated with the overuse of chemotherapy. 
Several promising biomarkers have emerged in CRC however, many have not made it to the clinic 
because they do not comply with daily practice. Conversely, the evaluation of dMMR has proven 
clinically feasible because the detection process is time and cost efficient. Importantly, CD147 
represents a clinically feasible biomarker because it can be similarly evaluated by IHC in FFPE 
samples. RT-qPCR is not yet routine in our hospital laboratories but can be performed in FFPE tissue 
and technological developments mean it might not be far away.  
 
4.8 CD147 AND MIR-21 IN THE LYMPH NODES OF STAGE II COLON CANCER 
The third objective of this study was to explore the expression levels of CD147 and miR-21 in the 
TDLNs of stage II colon cancer patients. This was under the hypothesis that tumour-associated 
expression of these markers might be present in the lymph nodes and could be indicators of pre-
metastatic spread. This is because miR-21 and CD147 have been characterised as blood-based tEV 
markers (56, 83) and tEVs are thought to be involved in the formation of the PMN in TDLNs (66). To 
the author’s knowledge, no other study has attempted to detect tEVs in human lymph node 
samples. While detecting tEVs in the lymph nodes of patients is technically difficult, this study 
highlights the difficulty of using potential surrogate markers for tEV detection in the lymph nodes.  
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As discovered, CD147 is expressed in the GCs of intestinal lymph nodes of non-cancer patient and 
the TDLNs of stage II colon cancer patients. However, this is likely a general process of the immune 
response that is not cancer associated. Data from The Human Protein Atlas originally lead us to 
believe CD147 is not expressed in unstimulated or stimulated (formation of GCs) (90) normal lymph 
nodes (unknown patient origin) and therefore could be a potential tEV marker. Conversely, the only 
other publication to demonstrate CD147 staining in normal lymph nodes found significant staining of 
GC B cells with weak to negative staining in follicle mantle zone and T cell zones (92).  
While it is not possible to tell whether the lymph nodes examined by Schmidt et al are non-cancer, 
healthy controls, our results suggest CD147 GC staining is not specific to cancer patients and is a 
general process of the immune response. This is in agreement with the BD Biosciences Human CD 
Marker Chart (91), where CD147 is expressed on human B cells. Put simply, CD147 cannot be used as 
a biomarker to detect tumour-associated expression or as a surrogate biomarker for tEVs in the 
lymph nodes of stage II colon cancer patients. Perhaps, it is more valuable to measure tEVs in the 
circulation of patients as this approach is more feasible (56).  
Interestingly, miR-21 may be more of a contender for the purpose of detecting tumour-associated 
expression of this marker. A key finding was the notably high expression of miR-21 in a small number 
of lymph nodes compared to control lymph nodes. These lymph nodes, which all came from 
different patients, demonstrated a 3-8-fold increase compared to control lymph nodes. Further, a 
greater variation in miR-21 levels was seen between lymph nodes of the same patient compared to 
the lymph nodes of the non-cancer patient. Importantly, previous studies investigating miR-21 in 
patients with B cell lymphomas have found miR-21 to be expressed at low levels in adjacent normal 
lymph nodes compared to B cell lymphoma tissue (117). Unfortunately, no other data can be found 
concerning the miR-21 expression levels of stimulated but healthy lymph nodes. Further, these 
findings are severely limited by the availability of control lymph nodes from a single patient.  
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Whether the findings that miR-21 is upregulated in some TDLNs is directly associated with the 
primary tumour, associated with a cancer-specific immune response or we have simply detected a 
non-specific immune response cannot be determined from this study. However, the association of 
miR-21 with blood-based tEVs (83) strengthens the hypothesis that upregulated levels in the lymph 
nodes of stage II colon cancer patients is cancer-specific.  
 
4.9 HISTOLOGICAL MORPHOLOGY OF STAGE II COLON CANCER LYMPH NODES 
4.9.1 INTRODUCTION 
The anti-tumour response in TDLNs may be particularly relevant to stage II patients. In cancer, 
particularly CRC, the TDLNs either serve as effective barriers or facilitators of dissemination of the 
primary tumour (72). Lymph node metastasis is the most important prognostic factor differentiating 
stage II and III CRC patients (72). However, some stage II patients have survival rates approximating 
stage III disease suggesting this prognostic factor is limited (13). Considering uninvolved TDLNs are 
the primary site for tumour antigen presentation and T cell/B cell activation (118), it is likely the type 
and extent of the immune response is important in tumour evolution. The TDLNs can generate both 
an anti-tumour and immunosuppressive response (118) which could be responsible for 
heterogenous outcomes in these patients and be an important prognostic factor. 
The most striking observation in the TDLNs of the stage II colon cancer patients, was the variation in 
number, size and shape of B cell primary follicles and GCs (secondary follicles). These spatially 
organised compartments, along with T cell zones and antigen-presenting cells, respond to the local 
tumour-associated immune signature within the draining lymph fluid (119). Depending on the 
signature, B cell and T cell compartments can expand or diminish and form the basis of the adaptive 
tumour-specific immune response (120). Specifically, the immunomodulating effects of B cell 
follicles and GCs change the composition of B memory and plasma cell populations that home back 
to the site of the tumour (120). While the effect of infiltrating immune cell populations has largely 
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focused on T cells, evidence is beginning to emerge for the importance of B cell mediated 
antitumour and protumourigenic effects (120). With a clinically feasible approach in mind, these B 
cell compartments were the most recognisable features and could be accurately quantified. 
Therefore, the focus of this project shifted to quantifying the histomorphological changes in distinct 
B cell compartments.  
4.9.2 QUALITATIVE OBSERVATIONS IN STAGE II,  III AND NON-CANCER TDLNS 
Qualitative comparison of B cell compartments within the TDLNs of stage II patients, the stage II 
patient and non-cancer patients revealed several interesting points. Firstly, nearly all stage II lymph 
nodes were under immune stimulation, characterised by the presence and abundance of B cell 
follicles and GCs. In contrast, only 1 out of 20 of the lymph nodes of the stage III patient were 
activated with the majority infiltrated with cancer. Secondly, the number of B cell follicles per lymph 
node in the stimulated lymph nodes of the stage II patients and the stage III patient were 
substantially higher than the non-cancer patient. However, relative to the size of the lymph node, 
the stage II and III follicles tended to be smaller. Further, the stage II and III follicles appeared to be 
more non-circular in shape, which has previously been described as GCs tending to “fuse” (121), 
compared to the non-cancer follicles. Lastly, striking variations in terms of the number and size of B 
cell follicles and GCs, were also seen within the stage II patients.  
Altogether, these qualitative observations suggest the B cell mediated immune potentiation within 
the TDLNs is specific and unique to stage II patients. This is in comparison to the stimulated lymph 
nodes of the non-cancer patient. The lack of lymph nodes that formed follicles and GCs in the stage 
III patient was likely to be a result of the infiltrating tumour. Further, the striking variation of the 
morphology of B cell compartments within the stage II patients support the idea for this being a 
potentially relevant prognostic factor in these patients.  
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4.9.3 COMPARISONS BETWEEN THE NUMBER AND SIZE OF B CELL COMPARTMENTS AND 
PATHOLOGICAL RISK FACTORS IN THE TDLNS OF STAGE II PATIENTS 
The number and size of B cell compartments in the TDLNs in stage II patients was associated with 
the presence of lymphatic invasion, dMMR and the extent of tumour T stage. Firstly, patients with a 
lower T stage, i.e T3 compared to T4a or T4b, tended to have smaller B cell follicles and GCs. Further, 
patients with lymphatic invasion tended to have smaller GCs and follicles. A significant association 
was also found between the number of GCs per lymph node (GC density) and lymphatic invasion 
although no pattern was observed for the number of B cell follicles per lymph nodes (follicle 
density). Lastly, patients with dMMR, had a significantly lower total follicle and primary follicle 
density, while no trends were seen for GC density or size.  
Despite this, no trends were observed between tumour grade and the number and size of B cell 
compartments. However, due to low patient numbers in the present study, patients with moderate 
tumour differentiation were considered high grade to allow comparisons between morphological 
features and tumour grade. Therefore, in a larger future cohort, stratification into all three groups: 
well, moderate and poorly differentiated tumours, may allow for more accurate associations to be 
seen.   
4.9.4 PREVIOUS FINDINGS FOR MORPHOLOGICAL CHANGES AND PROGNOSIS IN LYMPH 
NODES  
Morphological changes, including GC morphology, in the TDLN’s of CRC patients have been observed 
as early as 1975 (123, 124). However, the majority of these earlier studies failed to find any 
significant associations with GC and follicle morphology and prognosis in CRC populations consisting 
of all TNM stages. Interestingly, the one study that investigated these aspects by stage found a 
significant association between Duke’s stage B (stage II) patients with lymph nodes dominated by 
GCs and better survival (124). This association was not found for Duke’s stage A or D (stage I and IV) 
suggesting specificity of this phenomena to stage II and III patients. However, the prognostic 
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significance of the immune-modulating effects on B cell compartments in the TDLNs has likely 
changed. Great advances in CRC surgical techniques and adjuvant therapy have been made resulting 
in a substantial increase in the survival rate in the last 20 years (124).  
More recently, the current focus of CRC research in immunomodulating effects mainly addresses the 
role of the host immune response in the TME, such as infiltrating dendritic cells and T lymphocytes 
(120). The mechanisms behind morphological changes in the TDLNs- the primary site for T cell and B 
cell activation- is not well understood and has been poorly studied. Therefore, to our knowledge, 
there are no further publications investigating morphological changes in CRC. Recent insights into 
the lymph nodes of breast cancer and oral cancer patients however, may help us to understand how 
morphological patterns of B cell compartments are associated with prognosis. 
The most recent findings come from Seidl et al (2018) (73) who investigated various TDLNs 
morphological changes of 206 stage I-III breast cancer patients. To our knowledge, this is the only 
publication to assess the association between B cell compartment morphology and pathological risk 
factors. Consistent with the current findings, they found GC density was significantly associated with 
advanced T stage. However, we could not replicate the association they detected between follicle 
density and T stage. Further, the size of the follicles and GCs was not reported by Seidl et al. While 
we could not detect any trends or associations with tumour grade, potentially due to low sample 
size, Seidl et al detected a significant association between a high tumour grade and an elevated 
follicle and GC density. 
Beyond T stage and grade Seidl et al also explored associations between their morphological data 
and the molecular subtypes of breast cancer. These subtypes are based on hormone receptor and 
human epidermal growth factor 2 (HER2) status which are significantly associated with survival 
(141). The study demonstrated a significant association with the presence of oestrogen and/or 
progesterone receptors and lower GC and follicle density. Interestingly, both of these hormone 
receptors are associated with a relatively good prognosis (141). On the other hand, triple-negative 
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breast cancers (decrease in hormone receptors) were associated with a low density. This subtype is 
known to have the poorest prognosis.   
Combined with the associations detected with T stage, N stage and grade, the data from Seidl et al  
support the notion that more aggressive, higher-risk breast cancer types are associated with a higher 
follicle and GC density. While this is consistent with the direction of association between T stage and 
follicle density in the current study, the rest of our findings with dMMR status and lymphatic 
invasion, do not support those of Seidl et al. 
What could explain the discrepancies between these studies is the potential for lymph node 
morphological changes to be cancer type specific. In a study assessing the percentage of reactive 
follicles (equivalent to GC density) in the negative draining lymph nodes of non-metastatic oral 
cancer patients (stage I-III), a higher percentage of follicles was associated with a significantly better 
prognosis (74). Their logic behind this was the assumption that tumour-neoantigens predominately 
generate an anti-tumour response aimed to reduce the spread of the cancer. They also found, of all 
the histological features examined (LN area, capsule thickness, number of lobes, 
subcapsular/marginal sinuses and medullary sinuses, fibrotic and sinusoidal trabeculae), percentage 
of reactive follicles was the most predictive of time to death.  
4.9.5 POTENTIAL FUNCTIONAL DRIVING FORCE OF HISTOMORPHOLOGICAL CHANGES IN 
LYMPH NODES 
The exact mechanisms behind the spatial allocation and size of follicle and GC compartments and 
how this affects tumour immunology is not well understood. Only recently have B cells become 
appreciated as having an important role in tumour immunology (120). Before this, B cells were fairly 
out of focus and the prevailing notion was that T cells and innate immune cells primarily mediated 
antitumour immunity (125). The prognostic role of dense infiltration of CD8+ T cells in CRC is strong, 
particularly in stage I and II patients (126, 127) However, considering the lymph nodes are the 
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primary site for T cell activation (118), the involvement of a T cell-dependent B cell response in 
tumour immunology is likely.  
Of particular relevance are the associations between low infiltration of cytotoxic CD8+ T cells and a 
medium to low grade tumour, presence of lymphatic invasion and MSS tumours (126, 128, 129). 
While the exact mechanisms behind these associations have not fully been elucidated, it is 
speculated in MSI patients, the ability for their tumours to present a large amount of mutation-
generated neoantigens on the tumour cell surface stimulates T cell activity, ultimately leading to a 
TME rich in CD8+ T cells and Th1 helper cells (Th1) (129). This suggests a more intense immune 
response in these patients is associated with a better prognosis. 
In a B cell immunology context, the intense involvement of T lymphocytes suggest the B cell 
mediated immune response likely plays an important role in tumour evolution. Further, the 
association of altered T cell populations in the TME with different tumour pathological features is 
likely a result of altered T cell populations in the TDLNs. It is also known that specific CD4+ T cell 
populations are essential for the formation and maintenance of GCs as well as their output of 
memory cells and plasma cells (130). Taken together, it could be postulated that differences in 
tumour biology, with its association of altered T cell populations in the TDLN’s, would also affect the 
spatial allocation and size of follicle and GC compartments in a T-cell B cell dependent manner in the 
TDLNs. As such, the output of these morphological changes in B cell compartments could be a shift 
in B cell populations in the TDLNs and therefore TME. 
4.9.6 INFILTRATING B LYMPHOCYTES  
In terms of infiltrating B lymphocytes in the TME, evidence from animal models suggest B cells have 
both protumourigenic and antitumour effects (120). B cells have been shown to promote 
carcinogenesis through providing an inflammatory TME and attenuate chemotherapeutic affects and 
an antitumour immune response (131, 132, 133, 134). Conversely, B cells can inhibit tumour growth 
and metastasis (135). The many processes of B cells are likely attributable to their multiple functions 
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including the ability to secrete antibodies, present antigen, induce cytotoxic killing and promote and 
regulate T cell responses (120).  
Some evidence is beginning to emerge in CRC patients for the role of B cells in tumour biology (136, 
137). For example, a dense infiltration of CD20+ B cells has been negatively associated with 
metastasis and positively associated with a lower T stage and an improved OS (136). An increase in a 
CD138+ subset has been associated with a lower grade and MSS tumours (136). Taken together, this 
suggests the humoral immune response is also important in tumour biology and progression. Data 
matching B cell populations in the TME and TDLNs is lacking. However, evidence is beginning to 
emerge in mouse models of CRC in terms of tumour progression and changes in B cell populations in 
the TME and TDLNs (138).  
To briefly summarise, the role of T cell and B cell immunity in tumour biology and progression is 
inarguably important particularly in early stages of CRC. Thus, the primary site for T cell/B cell 
activation; the TDLN’s, is responsible for driving many of these protumourigenic and antitumour 
processes. Importantly, it has been postulated that whether B cells promote or inhibit tumour 
growth likely depends on temporal and spatial setting and the composition of B-cell subsets in the 
TDLNs.  
4.9.7 STRENGTHS AND LIMITATIONS 
It was not part of the original aim of this study to examine histomorphological patterns in the TDLNs 
and we believe the use of TMAs for this purpose is a potential limitation for the data analysis. It is 
not possible to determine whether 3mm diameter samples of each lymph node is truly 
representative of the donor tissue in terms of the number and size of follicles and GCs. 
 We also have concerns with the approach of measuring the size of follicles and GCs. We simply 
measured the diameter of these compartments on digitalised slides. Whether or not this represents 
the volume of these compartments is unknown. We believe it would important to involve a trained 




The data generated from the current study show the morphological patterns in B cell compartments 
of the TDLNs in stage II colon cancer patients have potential prognostic significance. While this area 
of our research is still well within the discovery phase, we have demonstrated how this potential 
biomarker can be detected and measured in a simple and clinically feasible approach. Further, 
qualitative assessments between non-cancer and stage II lymph nodes highlight the relevance of 
compartment morphology to stage II patients. Previous findings in breast and oral cancer and our 
general knowledge of cancer-immune interactions also support the potential prognostic role of 
compartment morphology in these patients. Again, due to our low sample size, specific associations 
with pathological risk factors warrant validation in a larger cohort. However, these associations raise 
interesting questions around the mechanisms behind the spatial allocation and size of B cell 
compartments and their outputs.  
 
4.10 SIGNIFICANCE OF FINDINGS  
The present study is the first in over 40 years to investigate morphological changes in B cell 
compartments of the TDLNs in colon cancer patients. Further, it is the first study to consider 
associations between these morphological changes and important pathological features including 
lymphatic invasion, dMMR, T stage and tumour grade. While these morphological changes as 
potential prognostic biomarkers are still well within the discovery phase, they are significant to this 
field of research for several reasons; Firstly, the TDLNs and the subsequent immune response is 
important and specifically relevant to early-stage colon cancer patients. Secondly, these 
morphological changes potentially carry information from both a B and T cell immunological 
perspective that could be more informative than standardised immunoscores in CRC. Lastly, this 
potential biomarker represents a simple, clinically feasible approach.  
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The most recent advancement in the prognostication of non-metastatic CRC has been the 
development and standardisation of an immunoscore that combines the measure of CD3+ and CD8+ 
T cell populations in the centre and invasive margin of the primary tumour (139).  The authors 
demonstrated the striking prognostic significance of this score with a multivariable-adjusted HR for 
time to recurrence of 0.40 (95% CI 0.30-0.54) for high versus low immunoscores. Importantly, this 
was independent of T staging, lymph node positivity, lymphatic invasion, tumour grade and MSI 
status. However, this immunoscore does not necessarily encompass the complexity of immune-
cancer interactions which can involve cells of the innate immune response as well as the 
underappreciated role of B cells, as previously discussed.  
We believe the morphological patterns of B cell compartments within the TDLNs could add valuable 
information to the immunoscore. The TDLNs are the primary site for tumour antigen presentation 
and subsequent T cell/B cell activation (118). Therefore, the TDLNs are the primary source of 
infiltrating lymphocytes at the tumour site. Further, the morphology of B cell compartments 
potentially carries information that combines the complex interactions of B cell and T cell 
populations which could be more informative than measuring the densities of two single lymphocyte 
populations. Despite this, our argument lacks clinical evidence that B cell immunology has a 
significant role in the development of CRC. As previously mentioned, evidence is only beginning to 
emerge from preclinical studies, therefore a large amount of exploration and validation of our 
potential biomarker is warranted. 
One important factor for implementation of biomarkers into clinical practice is proof of cost-
effectiveness and feasibility within a clinical laboratory workflow. While the immunoscore has been 
standardised across different laboratories, demonstrating its cost-effectiveness and feasibility within 
clinical laboratories is another challenge. However, here we have demonstrated how this potential 
biomarker can be measured in a simple and feasible manner. Theoretically, GCs and follicles can be 
visualised using a simple H&E stain, without the need for antibodies as demonstrated by Seidl and 
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colleagues (73). Importantly, TDLNs are already observed in clinical laboratories for cancer spread to 
determine the TNM staging of patients. Therefore, the additional data analysis could easily be 
implicated in everyday practice. 
 
4.11 OVERALL STRENGTHS AND LIMITATIONS OF THE STUDY  
The overall aim of this pilot study was to characterise the expression of specific biomarkers within 
the tumours and TDLNs of a small population of stage II colon cancer patients. Using miR-21 as an 
example, a critical aspect of this characterisation was understanding the tumour overexpression of 
miR-21 compared to adjacent normal mucosa. However, a limitation of the study design was the 
small sample size and therefore lack of statistical power. Therefore, the positive and negative 
findings within this study are not conclusive and can only be used to form hypotheses to inform 
future, larger studies. However, to reiterate, it was not the primary goal of this study to perform 
formal statistical analysis. Instead our aim was to establish techniques for biomarker detection and 
begin to characterise the expression of these markers in tumour and lymph node tissue.  
One important advantage of the present study was the access to fresh/frozen and formalin-fixed 
samples for majority of the patients recruited into the study. As mentioned, 3 out of 13 tumour and 
normal mucosa samples were not available due to their tumours being too small at the time of 
surgery. Despite this, the biobank has provided easy access to patient samples and a large amount of 
demographic and patient information stored within the RedCap database. Information, such as 
clinicopathological features, has been of high value within this study. Importantly, the value of the 
biobank in terms of patient numbers and the follow-up period of these patients is continuously 
increasing. Therefore, future, larger cohorts will be feasible within a short timeframe. 
In terms of the methodology used in the study a notable issue we encountered was the use of the 
TMAs for the detection of CD147 in tumour tissue and evaluation of histomorphology in the TDLNs. 
While TMAs are the standard for validation of prognostic biomarkers (140), for the discovery phase 
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of biomarkers, it is unknown whether a 3mm cylinder is representative of the donor tissue. 
Specifically, we were not able to accurately determine the extension/frequency of CD147 staining in 
tumour tissues due to dominance of cores with non-tumour tissue. Further, it is unknown whether 
the true prognostic significance of the number and size of lymph node B cell compartment can be 
obtained from 3mm cores.  
Similarly, while RT-qPCR has a high level of precision and reproducibility, whether it is the best suited 
methodology for the clinical detection and quantification of miRNAs is unknown. As mentioned, RT-
qPCR values represent the ‘average’ expression level of miRNAs across tumour cells and cell and 
tissue types including normal colon tissue (108). Methods such as ISH may be more appropriate as it 
considers the cell and tissue types as well as the subcellular location of the miRNAs.  
4.12 FUTURE DIRECTIONS  
This pilot study characterised potential prognostic biomarkers in a small population of stage II colon 
cancer patients. However, internal validation of these markers is warranted in a larger population of 
stage II colon cancer patients. The data from this pilot study can be used to not only drive 
hypotheses, but inform the design of a future, larger cohort to evaluate the prognostic significance 
of miR-21, CD147 and lymph node histomorphological characteristics. For example, a sample size of 
65 stage II colon cancer patients would be needed to test the following hypothesis: miR-21 relative 
expression levels are overexpressed in the tumours compared to paired normal mucosa tissue. This 
was calculated using a significance level of 0.05 and a power level of 0.9 and effect size calculated 
from the present study. To begin to assess the prognostication of these markers however, a bigger 
cohort would be required. The recurrence rate in stage II colon cancer patients is approximately only 
20-25% (20). Therefore, aspects such as these need to be considered in the design of a future cohort 
(142).  
The current study developed experimental techniques, of which some were primarily selected for 
their potential clinical utility, for the detection of specific biomarkers. However, as previously 
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mentioned, a limiting aspect of the detection of CD147 through IHC was the inability to accurately 
determine the extension of staining. Therefore, a critical next step would be to alleviate this problem 
by sampling the entire tissue as opposed to using TMAs. Some have suggested that full sections of 
the donor block should be used for accurate evaluation of staining frequency (140). A well-defined 
semiquantitative score, that combines both the intensity and frequency of staining, would not only 
enhance the clinical reproducibility of this technique but also partly address the issue of tumour 
heterogeneity (143).  
A future, larger cohort would also be critical to determine IHC and histomorphological scoring 
systems with the most prognostic significance to standardise the quantification of biomarkers. 
Previous publications use a variety of ordinal scoring methods that combine the intensity and 
extension of CD147 staining in IHC (44, 63, 64). Therefore, an important future step would be to 
explore these different scoring approaches in the same cohort of samples to determine the 
approach with the most prognostic significance. In terms of lymph node histomorphological 
evaluation, the few publications in this area (73, 74), have provided a starting point for this pilot 
study.  However, the novelty of this area warrants a significant amount of exploration of 
quantification approaches as well as the validity of using TMAs as previously mentioned. 
For biomarkers such as lymph node histomorphology, still well within the discovery phase, 
understanding the mechanisms behind the spatial allocation and densities of B cell populations may 
help to drive hypotheses to inform evaluation and scoring approaches. This might involve staining 
TDLNs for B cell populations known to infiltrate the tumour such as, CD20+ and CD38+ B 
lymphocytes (136) and T lymphocyte populations such as CD8+ 126). A larger number of positive 
(stage III) and negative controls (non-cancer related) would add value to these experiments. 
To address the limitations surrounding the use of RT-qPCR for the detection of miR-21, using ISH to 
detect miR-21 may be a future step. Some previous studies have employed ISH for the cellular and 
subcellular localisation of miR-21 but discrepancies exist likely due to insufficient validation of 
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probes (108). For example, miR-21 has been primarily detected in both stromal cells (108) and 
tumour cells (41). Future studies should develop and standardise ISH for the detection of miR-21 in 
stage II colon cancer patients. The development of this technique should determine the validity of 
RT-qPCR for prognostication or determine whether ISH is a more appropriate clinical test for this 
purpose. 
Finally, independent clinical validation using standardised methodologies and data analysis in a 
different cohort of samples is paramount (142). This would determine the reproducibility of these 
assays. Reproducibility across different laboratories is also critical to demonstrate the robustness 
and clinical feasibility of assays. Differences in sample processing as well as interpretation of data 
analysis would be expected. This is particularly important for evaluation of IHC as an example, where 
the analysis is manual and subjective to visual assessment and therefore susceptible to a certain 
level of observer bias and variability.  
4.13 CONCLUSION 
The overall aim of this pilot study was to explore and characterise the expression levels of CD147, 
miR-21 and miR-29a in the tumours and TDLNs of stage II colon cancer patients. There is an apparent 
need for prognostic biomarkers in this clinically heterogeneous population to guide their treatment 
decisions. Our data show CD147 and miR-21 are considerably dysregulated in the tumours of these 
patients, while we did not see any substantial variation for miR-29a. In the TDLNs of these patients, 
miR-21 levels appeared to be dysregulated compared to lymph nodes of a non-cancer patient. 
Conversely, tumour-specific CD147 expression was not distinguishable from immunological 
expression demonstrating the difficulties of using surrogate tEV markers in these tissues. Instead, 
the search for clinically feasible biomarkers in the TDLNs of these patients led us to explore 
histomorphological changes in B cell compartments. We found a large variation in the number and 
size of these compartments within stage II patients suggesting their observed clinical heterogeneity 
could be, impart due to immunological differences. Altogether, our results demonstrate clinically 
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feasible approaches for the detection and discovery of biomarkers and will help guide future, larger 
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